Search Result

Results for "

leukemia

" in MCE Product Catalog:

By Targets:	5-HT Receptor (1) Ack1 (1) ADC Antibody (3) ADC Cytotoxin (11) Adenosine Deaminase (2) Adenosine Receptor (1) Adrenergic Receptor (3) Akt (4) Amino Acid Derivatives (1) AMPK (4) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (12) Antibody-Drug Conjugates (ADCs) (3) Antifolate (9) Apoptosis (162) Arenavirus (1) Arp2/3 Complex (1) Aurora Kinase (6) Autophagy (20) Bacterial (17) Bcl-2 Family (19) Bcr-Abl (22) BCRP (1) Btk (8) c-Fms (3) c-Kit (5) c-Myc (1) Cannabinoid Receptor (1) Casein Kinase (6) Caspase (9) CCR (1) CD19 (1) CD22 (3) CD3 (1) CDK (18) COX (1) CRM1 (1) CXCR (1) Cytochrome P450 (2) Deubiquitinase (2) Dihydroorotate Dehydrogenase (7) DNA Alkylator/Crosslinker (11) DNA Methyltransferase (7) DNA/RNA Synthesis (27) Dopamine Receptor (3) Drug Metabolite (7) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (7) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) Endogenous Metabolite (13) Epigenetic Reader Domain (37) ERK (2) Eukaryotic Initiation Factor (eIF) (3) Farnesyl Transferase (1) FGFR (4) FLT3 (48) Fluorescent Dye (1) Fungal (1) Galectin (1) GSK-3 (6) HDAC (17) Histone Acetyltransferase (2) Histone Demethylase (21) Histone Methyltransferase (22) HIV (3) HSP (2) HSV (2) IAP (1) IFNAR (1) Integrin (4) Interleukin Related (4) Isocitrate Dehydrogenase (IDH) (4) JAK (9) Keap1-Nrf2 (2) Kinesin (3) KLF (1) Lactate Dehydrogenase (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) Lipoxygenase (2) MAP4K (1) MDM-2/p53 (6) MEK (2) MicroRNA (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (5) Mitophagy (4) MNK (1) Monoamine Oxidase (2) mTOR (2) NF-κB (1) NO Synthase (1) Notch (5) Nuclear Factor of activated T Cells (NFAT) (1) Nucleoside Antimetabolite/Analog (7) Orthopoxvirus (1) P-glycoprotein (4) p38 MAPK (3) Parasite (5) PARP (1) PDGFR (9) PERK (3) Phosphatase (2) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (12) Pim (2) PKC (1) Polo-like Kinase (PLK) (6) Potassium Channel (3) PROTACs (17) Proteasome (2) RANKL/RANK (1) RAR/RXR (1) Ras (2) Reactive Oxygen Species (2) RET (2) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) Salt-inducible Kinase (SIK) (1) SARS-CoV (4) Ser/Thr Protease (1) Sirtuin (1) Somatostatin Receptor (1) SphK (2) Src (6) STAT (10) Syk (4) TAM Receptor (4) TET Protein (1) TNF Receptor (4) Topoisomerase (15) Trk Receptor (3) VEGFR (2)
By Research Areas:	Cancer (511) Cardiovascular Disease (8) Endocrinology (3) Infection (39) Inflammation/Immunology (44) Metabolic Disease (4) Neurological Disease (14)

By Targets:

5-HT Receptor (1)

Ack1 (1)

ADC Antibody (3)

ADC Cytotoxin (11)

Adenosine Deaminase (2)

Adenosine Receptor (1)

Adrenergic Receptor (3)

Akt (4)

Amino Acid Derivatives (1)

AMPK (4)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (12)

Antibody-Drug Conjugates (ADCs) (3)

Antifolate (9)

Apoptosis (162)

Arenavirus (1)

Arp2/3 Complex (1)

Aurora Kinase (6)

Autophagy (20)

Bacterial (17)

Bcl-2 Family (19)

Bcr-Abl (22)

BCRP (1)

Btk (8)

c-Fms (3)

c-Kit (5)

c-Myc (1)

Cannabinoid Receptor (1)

Casein Kinase (6)

Caspase (9)

CCR (1)

CD19 (1)

CD22 (3)

CD3 (1)

CDK (18)

COX (1)

CRM1 (1)

CXCR (1)

Cytochrome P450 (2)

Deubiquitinase (2)

Dihydroorotate Dehydrogenase (7)

DNA Alkylator/Crosslinker (11)

DNA Methyltransferase (7)

DNA/RNA Synthesis (27)

Dopamine Receptor (3)

Drug Metabolite (7)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (7)

E3 Ligase Ligand-Linker Conjugates (2)

EGFR (1)

Endogenous Metabolite (13)

Epigenetic Reader Domain (37)

ERK (2)

Eukaryotic Initiation Factor (eIF) (3)

Farnesyl Transferase (1)

FGFR (4)

FLT3 (48)

Fluorescent Dye (1)

Fungal (1)

Galectin (1)

GSK-3 (6)

HDAC (17)

Histone Acetyltransferase (2)

Histone Demethylase (21)

Histone Methyltransferase (22)

HIV (3)

HSP (2)

HSV (2)

IAP (1)

IFNAR (1)

Integrin (4)

Interleukin Related (4)

Isocitrate Dehydrogenase (IDH) (4)

JAK (9)

Keap1-Nrf2 (2)

Kinesin (3)

KLF (1)

Lactate Dehydrogenase (1)

Ligands for E3 Ligase (1)

Ligands for Target Protein for PROTAC (2)

Lipoxygenase (2)

MAP4K (1)

MDM-2/p53 (6)

MEK (2)

MicroRNA (1)

Microtubule/Tubulin (4)

Mitochondrial Metabolism (5)

Mitophagy (4)

MNK (1)

Monoamine Oxidase (2)

mTOR (2)

NF-κB (1)

NO Synthase (1)

Notch (5)

Nuclear Factor of activated T Cells (NFAT) (1)

Nucleoside Antimetabolite/Analog (7)

Orthopoxvirus (1)

P-glycoprotein (4)

p38 MAPK (3)

Parasite (5)

PARP (1)

PDGFR (9)

PERK (3)

Phosphatase (2)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

PI3K (12)

Pim (2)

PKC (1)

Polo-like Kinase (PLK) (6)

Potassium Channel (3)

PROTACs (17)

Proteasome (2)

RANKL/RANK (1)

RAR/RXR (1)

Ras (2)

Reactive Oxygen Species (2)

RET (2)

Reverse Transcriptase (1)

Ribosomal S6 Kinase (RSK) (1)

Salt-inducible Kinase (SIK) (1)

SARS-CoV (4)

Ser/Thr Protease (1)

Sirtuin (1)

Somatostatin Receptor (1)

SphK (2)

Src (6)

STAT (10)

Syk (4)

TAM Receptor (4)

TET Protein (1)

TNF Receptor (4)

Topoisomerase (15)

Trk Receptor (3)

VEGFR (2)

By Research Areas:

Cancer (511)

Cardiovascular Disease (8)

Endocrinology (3)

Infection (39)

Inflammation/Immunology (44)

Metabolic Disease (4)

Neurological Disease (14)

520

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas

HY-152470

*Eleven-Nineteen-Leukemia* Protein IN-2**	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-2 (compound 23) is an Eleven-Nineteen-Leukemia Protein (ENL) inhibitor with an IC₅₀ value of 10.7 nM. Eleven-Nineteen-Leukemia Protein IN-2 can be used for the research of leukemia.

HY-152469

*Eleven-Nineteen-Leukemia* Protein IN-1**	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-1 is an inhibitor of ENL YEATS domain with an IC₅₀ value of 14.5 nM. Eleven-Nineteen-Leukemia Protein IN-1 interacts with ENL protein and enhances the thermal stability of ENL protein in vitro.

HY-152471

*Eleven-Nineteen-Leukemia* Protein IN-3**	Epigenetic Reader Domain	Cancer
Eleven-Nineteen-Leukemia Protein IN-3 is an orally active inhibitor of ENL YEATS domain with an IC₅₀ value of 15.4 nM. Eleven-Nineteen-Leukemia Protein IN-3 down-regulates MYC expression through ENL in cells and can enhances the thermal stability of ENL protein in vitro.

HY-13216

Pyroxamide	HDAC Apoptosis	Cancer
Pyroxamide is a potent inhibitor of histone deacetylase 1 (HDAC1) with an ID₅₀ of 100 nM. Pyroxamide can induce apoptosis and cell cycle arrest in leukemia.

HY-145904

PDGFRα/FLT3-ITD-IN-3	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of 0.153 and 0.004 μM, respectively. PDGFRα/FLT3-ITD-IN-3 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.

HY-145902

PDGFRα/FLT3-ITD-IN-1	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-1 (Compound 12d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 0.036 and 0.003 μM, respectively. PDGFRα/FLT3-ITD-IN-1 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.

HY-145903

PDGFRα/FLT3-ITD-IN-2	PDGFR FLT3	Cancer
PDGFRα/FLT3-ITD-IN-2 (Compound 13d) is a potent inhibitor of PDGFRα/FLT3 with IC₅₀s of more than 20 and 1.654 μM, respectively. PDGFRα/FLT3-ITD-IN-2 has the potential for the research of acute myeloid leukemia or chronic eosinophilic leukemia.

HY-119784

Eupenifeldin	Others	Cancer
Eupenifeldin is pentacyclic bistropolone isolated from cultures of Eupenicillium brefeldianum ATCC 74184. Eupenifeldin is cytotoxic against the HCT-116 cell line. Eupenifeldin has the potential for the research of leukemia.

HY-109539

Gemtuzumab ozogamicin	Antibody-Drug Conjugates (ADCs)	Cancer
Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) consisting of a cytotoxic derivative of Calicheamicin, and a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.

HY-126030

(+)-Syringaresinol	Nuclear Factor of activated T Cells (NFAT)	Cancer
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC₅₀ of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia.

HY-145690

HP1328	FLT3	Cancer
HP1328 is a potent inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1328 is a benzoimidazole scaffold-based compound. HP1328 significantly reduces the leukemia burden and prolongs the survival of mice with FLT3/ITD leukemia.

HY-146002

IDH2R140Q-IN-1	Isocitrate Dehydrogenase (IDH)	Cancer
IDH2R140Q-IN-1 (compound C6) is a potent inhibitor of IDH2^R140Q, with an IC₅₀ of 6.1 nM. IDH2R140Q-IN-1 can be used for the research of acute myeloid leukemia.

HY-148036

FLT3-IN-16
FLT3 Cancer

FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia.

FLT3-IN-16	FLT3	Cancer
FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia.

HY-135664

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia.

HY-N10206

11-epi-Chaetomugilin I	Endogenous Metabolite	Cancer
11-epi-Chaetomugilin I is a metabolite found in Chaetomium globosum. 11-epi-Chaetomugilin I exhibits significant cytotoxic activity against the murine P388 leukemia cell line, the human HL-60 leukemia cell line, the murine L1210 leukemia cell line, and the human KB epidermoid carcinoma cell line.

HY-141677

INCB059872	Histone Demethylase	Cancer
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia.

HY-141677A

INCB059872 dihydrochloride	Histone Demethylase	Cancer
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia.

HY-148026

Sonrotoclax BGB 11417	Bcl-2 Family	Cancer
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines.

HY-136175

Revumenib SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

HY-10939A

(-)-15-Deoxyspergualin trihydrochloride	Others	Cancer
(-)-15-Deoxyspergualin trihydrochloride is a potent antitumor agent. (-)-15-Deoxyspergualin trihydrochloride shows strong inhibition against mouse leukemia L-1210.

HY-10939

(-)-15-Deoxyspergualin
Others Cancer

(-)-15-Deoxyspergualin is a potent antitumor agent. (-)-15-Deoxyspergualin shows strong inhibition against mouse leukemia L-1210.

(-)-15-Deoxyspergualin	Others	Cancer
(-)-15-Deoxyspergualin is a potent antitumor agent. (-)-15-Deoxyspergualin shows strong inhibition against mouse leukemia L-1210.

HY-148676

Menin-MLL inhibitor 26	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 26 is a Menin-MLL inhibitor. Menin-MLL inhibitor 26 also is an active reference. Menin-MLL inhibitor 26 can inhibits cell growth. Menin-MLL inhibitor 26 can be used for the research of leukemia.

HY-12344

UNC2025	FLT3	Cancer
UNC2025 is a potent, ATP-competitive and highly orally active Mer/Flt3 inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 exhibits an excellent PK properties, and can be used for the investigation of acute leukemia.

HY-145691

HP1142	FLT3	Cancer
HP1142 is a potent and selective inhibitor of FLT3 receptor tyrosine kinase (FLT3/ITD mutation). HP1142 is a benzoimidazole scaffold-based compound. HP1142 has the potential for the research of FLT3/ITD leukemia.

HY-152036

SIAIS100
PROTACs Bcr-Abl Cancer

SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML).

SIAIS100	PROTACs Bcr-Abl	Cancer
SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC₅₀ value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML).

HY-N7761

Trijuganone B Tetrahydro tanshinone I	Others	Cancer
Trijuganone B (Tetrahydro tanshinone I) can be extracted from from the roots of Salvia miltiorrhiza f. alba. Trijuganone B inhibits the proliferation of leukemia cells.

HY-148813

AK-2292	PROTACs STAT	Cancer
AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC₅₀ of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models.

HY-141680

CPS2
CDK Cancer

CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC₅₀= 24 nM). CPS2 can be used for the research of acute myeloid leukemia.

CPS2	CDK	Cancer
CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC₅₀= 24 nM). CPS2 can be used for the research of acute myeloid leukemia.

HY-P99207

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

HY-143278

FLT3-IN-13	Topoisomerase FLT3 Apoptosis	Cancer
FLT3-IN-13 (compound 20) is a potent and effective antileukemic topoisomerase II and FLT3 dual inhibitor with IC₅₀ values of 2.26 μM and 2.26 μM, respectively. FLT3-IN-13 arrests cell cycle at G2/M phase and induce apoptosis. FLT3-IN-13 has anticytotoxic activity, particularly against leukemia.

HY-129983

5-Hydroxymethyl-2'-deoxyuridine	HSV	Cancer Infection
5-Hydroxymethyl-2'-deoxyuridine is a nucleoside analog. 5-Hydroxymethyl-2'-deoxyuridine inhibits the replication of multiple human leukemia cell lines with IC₅₀ values of 1.7-5.8 μM. 5-Hydroxymethyl-2'-deoxyuridine prolongs the survival of mice carrying L1210 leukemia. 5-Hydroxymethyl-2'-deoxyuridine can be used for the research of cell replication and leukemia.

HY-101248

GR-46611
5-HT Receptor Cancer

GR-46611 is a 5-HT_1D receptor agonist. GR-46611 can be used in the research of bladder hyperactivity, leukemia.

GR-46611	5-HT Receptor	Cancer
GR-46611 is a 5-HT_1D receptor agonist. GR-46611 can be used in the research of bladder hyperactivity, leukemia.

HY-N0128

Sclareol	Apoptosis	Cancer
Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia (P-388), human epidermal carcinoma (KB) cells and human leukemia cell lines. Sclareol induces cell apoptosis.

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia.

HY-18949

JI6	FLT3 JAK c-Kit	Cancer
JI6 is a potent, selective and orally active FLT3 inhibitor, with IC₅₀s of ∼40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC₅₀s of ∼250 and ∼500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia.

HY-N8386

Berkeleylactone F
Antibiotic Cancer Infection

Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells.

Berkeleylactone F	Antibiotic	Cancer Infection
Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells.

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.

HY-129407A

AAF-CMK	Ser/Thr Protease Apoptosis	Cancer
AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research.

HY-151211

BTK-IN-16	Btk	Cancer Inflammation/Immunology
BTK-IN-16 is a dual inhibitor of BTK wild type and C481S mutant of Bruton’s tyrosine kinase (BTK) with IC₅₀s of 5.1 and 4.1 μM. BTK-IN-16 can be used for the research of autoimmune diseases and chronic lymphocytic leukemia.

HY-P99034

Moxetumomab
ADC Antibody CD22 Cancer Inflammation/Immunology

Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL).

Moxetumomab	ADC Antibody CD22	Cancer Inflammation/Immunology
Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL).

HY-119182

Mitonafide NSC 300288	DNA/RNA Synthesis	Cancer
Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia.

HY-78884

Anticancer agent 9	Amino Acid Derivatives	Cancer
Anticancer agent 9, a glycine derivative, is an anticancer agent. Anticancer agent 9 can inhibit tumor cells viability of myelogenous leukemia and human prostate cancer.

HY-14519

Methotrexate Amethopterin; CL14377; WR19039	Antifolate DNA/RNA Synthesis ADC Cytotoxin Apoptosis Bacterial	Cancer Inflammation/Immunology
Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia).

HY-14519D

Methotrexate monohydrate Amethopterin monohydrate; CL14377 monohydrate; WR19039 monohydrate	Antifolate DNA/RNA Synthesis ADC Cytotoxin Apoptosis Bacterial	Cancer Inflammation/Immunology
Methotrexate (Amethopterin) monohydrate, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate monohydrate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia).

HY-141480

GSK-3β inhibitor 3	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia.

HY-P99285

Denintuzumab hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

HY-12344A

UNC2025 hydrochloride	FLT3	Cancer
UNC2025 hydrochloride is a potent, ATP-competitive, and highly orally active Mer/Flt3 inhibitor with IC₅₀ values of 0.74 nM and 0.8 nM, respectively. UNC2025 hydrochloride is >45-fold selectivity for MERTK relative to Axl (IC₅₀= 122 nM; K_i = 13.3 nM). UNC2025 hydrochloride exhibits an excellent PK properties, and can be used for the investigation of acute leukemia.

HY-14519A

Methotrexate disodium Amethopterin disodium; CL14377 disodium; WR19039 disodium	Antifolate DNA/RNA Synthesis ADC Cytotoxin Apoptosis Bacterial	Cancer Inflammation/Immunology
Methotrexate (Amethopterin) disodium, an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate disodium, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia).

HY-129167

Menin-MLL inhibitor 4	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 4 is an inhibitor of *Menin- MLL (mixed-lineage leukemia* protein) interaction** extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity.

HY-141797

MS33	Histone Methyltransferase PROTACs	Cancer
MS33 is a potent WDR5 degrader, with K_ds of 870 nM and 120 nM for VCB and WDR5, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia.

HY-150109

Purinostat mesylate	HDAC Apoptosis	Cancer
Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC₅₀s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia.

HY-18948

GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
GSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia.

HY-146886

FLT3-IN-15	FLT3	Cancer
FLT3-IN-15 is a highly potent and orally active FLT3 inhibitor with IC₅₀s of 0.87 nM and 0.32 nM for FLT3 and FLT3/D835Y, respectively. FLT3-IN-15 can be used for researching acute myeloid leukemia.

HY-144371

DHODH-IN-20	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer Inflammation/Immunology
DHODH-IN-20 (Compound 133) is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-20 inhibits tumor growth. DHODH-IN-20 has the potential for the research of acute myelogenous leukemia.

HY-151259

TK4b	JAK	Cancer
TK4b is a Janus kinase (JAK) inhibitor with the IC₅₀ values of 19.40 nM and 18.42 nM for JAK2 and JAK3, respectively. TK4b can be used in lymphoid-derived diseases and leukemia cancer research.

HY-151258

TK4g	JAK	Cancer
TK4g is a Janus kinase (JAK) inhibitor with the IC₅₀ values of 12.61 nM and 15.80 nM for JAK2 and JAK3, respectively. TK4g can be used in lymphoid-derived diseases and leukemia cancer research.

HY-N7651

Neoanhydropodophyllol	Others	Cancer
Neoanhydropodophyllol is a cyclolignan derivative, with antineoplastic activity. Neoanhydropodophyllol displays cytotoxicity against several cancer cells (leukemia, lung carcinoma and colon carcinoma).

HY-128068

DHODH-IN-17	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC₅₀=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML).

HY-152133

PROTAC HDAC6 degrader 1	PROTACs HDAC Apoptosis	Cancer
PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC₅₀ of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines.

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia.

HY-147414

Vamotinib PF-114	Bcr-Abl	Cancer
Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia.

HY-N2387

Pinosylvin	Bacterial Apoptosis Autophagy	Cancer Infection
Pinosylvin is a pre-infectious stilbenoid toxin isolated from the heartwood of Pinus species, has anti-bacterial activities. Pinosylvin is a resveratrol analogue, can induce cell apoptosis and autophapy in leukemia cells.

HY-101025

Nrf2-IN-1
Keap1-Nrf2 Cancer

Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML).

HY-101985

BV02	Bcr-Abl	Cancer
BV02 is a potent 4-3-3 PPI (14-3-3 protein–protein interaction) inhibitor. BV02 shows cytotoxicity for hematopoietic cells expressing the IM (imatinib mesylate)-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. BV02 has the potential for the research of chronic myeloid leukemia.

HY-147513

AKT-IN-12	Akt Apoptosis	Cancer
AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC₅₀ value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia.

HY-16786

AI-10-49	Others	Cancer Inflammation/Immunology
AI-10-49 is an inhibitor of leukemic oncoprotein CBFβ-SMHHC. AI-10-49 inhibits the binding of CBFβ-SMMHCto the RUNX1 Runt domain with IC₅₀ value of 0.26 μM. AI-10-49 can be used for the research of leukemia.

HY-114162A

VTP50469 fumarate	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 fumarate has potently anti-leukemia activity.

HY-114162

VTP50469	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity.

HY-P99014

Cusatuzumab	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML).

HY-145723

MAX-40279	FLT3 FGFR	Cancer Inflammation/Immunology
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

HY-145723A

MAX-40279 hydrochloride	FLT3 FGFR	Cancer Inflammation/Immunology
MAX-40279 hydrochloride is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

HY-19095

TNP-351	Antifolate	Cancer
TNP-351 is an antifolate. TNP-351, a dihydrofolate reductase (DHFR) inhibitor, has potent antitumor activity against not only leukemia cells but also solid tumor cells in vitro and in vivo.

HY-145723B

MAX-40279 hemifumarate	FLT3 FGFR	Cancer Inflammation/Immunology
MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

HY-145723C

MAX-40279 hemiadipate	FLT3 FGFR	Cancer Inflammation/Immunology
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).

HY-N0564

Notopterol	Apoptosis	Cancer Inflammation/Immunology Neurological Disease
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML).

HY-139535

Luxeptinib CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells.

HY-102010

Pancratistatin (+)-Pancratistatin	Apoptosis	Cancer
Pancratistatin is an isoquinoline alkaloid that can be isolated from Hymenocallis littoralis. Pancratistatin induces apoptosis of human melanoma cells. Pancratistatin can be used for the research of neuroblastoma, leukemia and breast cancer.

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Cancer Inflammation/Immunology
JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC₅₀s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia.

HY-103275

Adaphostin NSC 680410	Bcr-Abl Apoptosis	Cancer
Adaphostin (NSC 680410), the adamantyl ester of AG957, is a potent p210^bcr/abl inhibitor (IC₅₀=14 μM). Adaphostin induces apoptosis in T-lymphoblastic human leukemia cell lines (IC₅₀ ranging from 17 to 216 nM). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Adaphostin increased the level of reactive oxygen species (ROS) within CLL B cells.

HY-N10364

6β,7β-Epoxyasteriscunolide A	Others	Cancer
6β,7β-Epoxyasteriscunolide A, a sesquiterpenoid, shows cytotoxicity against the HL-60 and MOLT-3 leukemia cell lines, with IC₅₀s range 4.1-5.4 μM.

HY-108969

Pyrazoloacridine NSC 366140; PD 115934	Topoisomerase Apoptosis	Cancer
Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC₅₀ of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment.

HY-136360

MI-3454	Epigenetic Reader Domain	Cancer
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC₅₀ of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis.

HY-112218

MIK665
S-64315
Bcl-2 Family Cancer

MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC₅₀ of 1.81 nM for MCL1.

HY-19554

MM-401	Histone Methyltransferase Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs).

HY-101150A

sulfo-DGN462 sodium	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).

HY-118365

NSC 140873	Others	Cancer Infection
NSC 140873 is an inhibitor of the RUNX1-CBFβ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335).

HY-N1830

3-Epiwilsonine
Others Cancer

3-Epiwilsonine is an alkaloid from Cephalotaxus wilsoniana, exhibits effect on acute and chronic myeloid leukemia and malignant lymphoma.

HY-135909

TH1217 ZINC1775962367	SARS-CoV	Cancer Infection
TH1217 (ZINC1775962367) is a potent and selective dCTPase pyrophosphatase 1 (dCTPase) inhibitor, with an IC₅₀ of 47 nM. TH1217 enhances the cytotoxic effect of cytidine analogues in leukemia cells. TH1217 also could modulate SARS-Cov-2 interactors, so it shows activity of against COVID-19.

HY-124629

DB2313	Apoptosis	Cancer
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects.

HY-19554A

MM-401 TFA	Histone Methyltransferase Apoptosis	Cancer
MM-401 (TFA) is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

HY-112041

Unesbulin PTC596	Apoptosis	Cancer
Unesbulin (PTC596) is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. Unesbulin downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia (AML) cells. Unesbulin has anti-leukemic activity.

HY-151634

Syk-IN-6	Syk STAT ERK	Cancer
Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML).

HY-120504

N-Acetyltyramine	Bacterial	Cancer Infection
N-Acetyltyramine is a quorum-sensing inhibitor (QSI) compound produced by V. alginolyticus M3-10. N-Acetyltyramine is capable of inhibiting the QS of C. violaceum ATCC 12472. N-acetyltyramine reverses resistance in Doxorubicin-resistant leukemia P388 cells.

HY-109184

Murizatoclax AMG 397	Bcl-2 Family	Cancer
Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of *myeloid leukemia* 1 (MCL-1) inhibitor, with a K_i** of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members. Murizatoclax can be used for the research of cancer.

HY-101266B

Milademetan tosylate hydrate DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis.

HY-101266

Milademetan DS-3032	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.

HY-50868

Bafetinib INNO-406; NS-187	Bcr-Abl Src Apoptosis	Cancer
Bafetinib is a potent and orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib augments the activities of several proapoptotic Bcl-2 homology (BH)3-only proteins (Bim, Bad, Bmf and Bik) and induces apoptosis in Ph⁺ leukemia cells via Bcl-2 family-regulated intrinsic apoptosis pathway.

HY-106556

Zorubicin Rubidazon; Rubidazone	DNA/RNA Synthesis Topoisomerase	Cancer
Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas.

HY-151560

hDHODH-IN-11	Lactate Dehydrogenase	Cancer
hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC₅₀ value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML).

HY-14661

SB-743921 free base	Kinesin	Cancer
SB-743921 free base is a potent selective inhibitor of the mitotic kinesin KSP (Eg5), with a K_i of 0.1 nM. SB-743921 free base can induce mitotic arrest, block cell cycle progression, induce apoptosis, and can be used in the research of myeloma, leukemia and other diseases.

HY-120395

UC-514321	STAT Apoptosis TET Protein	Cancer Inflammation/Immunology
UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.

HY-N9210

1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid	Others	Cancer
1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid, a ellagic acid derivative of Agrostistachys hookeri, exhibits activity against cultured P-388 lymphocytic leukemia cells.

HY-13739

Ranimustine
MCNU
DNA Alkylator/Crosslinker Cancer

Ranimustine (MCNU) is a nitrosourea alkylating agent, can be used for research of chronic myelogenous leukemia and polycythemia vera.

HY-P99971

Gemtuzumab	Antibody-Drug Conjugates (ADCs)	Cancer
Gemtuzumab (Gemtuzumab ozogamicin) is an antibody-drug conjugate targeting to CD33 on tumor cells. Gemtuzumab consists of a cytotoxic derivative of calicheamicin and a humanised monoclonal IgG4 antibody. CD33 is specifically expresses on the surface of leukaemic cell blasts in acute myeloid leukemia (AML) patients. Gemtuzumab can be used for research of AML.

HY-149031

DHODH-IN-22	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML).

HY-123578

NSC689857	EGFR E1/E2/E3 Enzyme	Cancer
NSC689857 is a potent EGFR and SCF^SKP2 inhibitor with an IC₅₀ value of 36 μM for Skp2-Cks1. NSC689857 can inhibit p27 ubiquitylation (IC₅₀=30 μM). NSC689857 has varied activity across cancer types, with more activity against leukemia cell lines than others.

HY-121412

Lankacidin C	Antibiotic Bacterial	Cancer Infection
Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity.

HY-124676A

DB2115 tertahydrochloride	Apoptosis	Cancer
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.

HY-137460

Vodobatinib K0706	Bcr-Abl	Cancer
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC₅₀ of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research.

HY-132200

UNC5293	TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3	Cancer
UNC5293 is a MERTK-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC₅₀=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.

HY-139996

Pomalidomide-C5-Dovitinib	PROTACs Ligands for E3 Ligase	Cancer
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD⁺ acute myeloid leukemia.

HY-145409

SR-0813	Epigenetic Reader Domain	Cancer
SR-0813 is a potent and selective ENL/AF9 YEATS domain inhibitor. SR-0813 has IC₅₀ and EC₅₀ values of 25 nM and 205 nM for ENL YEATS domain, respectively. SR-0813 has IC₅₀ and EC₅₀ values of 311 nM and 76 nM (CETSA) for AF9 YEATS domain, respectively. SR-0813 binds MAP3K19 with over 100-fold lower affinity (K_d=3.5 μM) than ENL YEATS (K_d=30 nM). SR-0813 can be used for the research of acute leukemia.

HY-114312

MD-224	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (MDM2) degrader based on the proteolysistargeting chimera (PROTAC) concept. MD-224 consists of ligands for Cereblon and MDM2. MD-224 induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells, and achieves an IC₅₀ value of 1.5 nM in inhibition of growth of RS4;11 cells. MD-224 has the potential to be a new class of anticancer agent.

HY-19527

IST5-002 N6-Benzyladenosine-5'-phosphate	STAT Apoptosis	Cancer
IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b (IC₅₀s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML).

HY-101519

BETd-260 ZBC 260	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
BETd-260 (ZBC 260) is a PROTAC connected by ligands for Cereblon and BET, with as low as 30 pM against BRD4 protein in RS4;11 leukemia cell line. BETd-260 potently suppresses cell viability and robustly induces apoptosis in hepatocellular carcinoma (HCC) cells.

HY-D0153

Tetramethylrhodamine-5-isothiocyanate	Fluorescent Dye	Cancer
Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles.

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells.

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells.

HY-13732

Prednimustine Leo 1031; NSC 134087	DNA Alkylator/Crosslinker	Cancer
Prednimustine (Leo 1031;NSC 134087) is the ester formed from Prednisolone (HY-17463) and Chlorambucil (HY-13593). Prednimustine can be used for leukemias and lymphomas research.

HY-108470

Ro5-3335	Others	Cancer
Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation.

HY-138831

AES-350	HDAC Apoptosis	Cancer
AES-350 is a potent and orally active HDAC6 inhibitor with an IC₅₀ and a K_i of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC₅₀ values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research.

HY-16379A

Pacritinib hydrochloride SB-1518 hydrochloride	JAK	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC₅₀=23 nM) and JAK2^V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF).

HY-151426

Anticancer agent 83	Apoptosis	Cancer
Anticancer agent 83 is a potent anticancer agent, inhibits LOX IMVI cells growth with a GI₅₀ value of 0.15 mM. Anticancer agent 83 reduces mitochondrial membrane potential and induces DNA damage to induces leukemia cells apoptosis.

HY-147327

N-Formylsarcolysine	Others	Cancer
N-Formylsarcolysine has antitumor activity, and inhibits leukemia by increasing the Hb and erythrocyte levels and decreasing the number of leukocytes. N-Formylsarcolysine also involves in glioblastoma and other diseases research.

HY-10082A

(E)-3-AP (E)-PAN-811; (E)-NSC# 663249; (E)-OCX191	DNA/RNA Synthesis	Cancer
(E)-3-AP is the E configuration of 3-AP. 3-AP is a potent ribonucleotide reductase inhibitor. 3-AP shows anti-proliferative activity. 3-AP shows anticancer activity in L1210 leukemia model. 3-AP inhibits RR activity and DNA synthesis.

HY-150772

Tubulin/HDAC-IN-1	Microtubule/Tubulin HDAC Apoptosis Mitochondrial Metabolism	Cancer
Tubulin/HDAC-IN-1 is a dual tubulin and HDAC-IN-1 inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC₅₀: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia.

HY-134481

FLT3-IN-10	FLT3	Cancer
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML).

HY-W077242

1,4-Anthraquinone	DNA/RNA Synthesis	Cancer
1,4-Anthraquinone is a potent anticancer agent. 1,4-Anthraquinone blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of cancer cells. 1,4-Anthraquinone can be used to research anti-leukemia.

HY-N1649

2,3,2'',3''-Tetrahydroochnaflavone	Others	Cancer
2,3,2'',3''-Tetrahydroochnaflavone is a biflavonoid, which can be isolated from the leaves of Quintinia acutifolia. 2,3,2'',3''-Tetrahydroochnaflavone shows some cytotoxicity against P388 murine lymphocytic leukemia cells, with an IC₅₀ of 8.2 µg/mL.

HY-121725

MM-206	STAT	Cancer
MM-206, a STAT3 activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC₅₀ of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines.

HY-123794

MP07-66	Phosphatase	Cancer
MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation.

HY-127103

FB23-2	Apoptosis	Cancer
FB23-2 is a potent and selective inhibitor of mRNA N⁶-methyladenosine (m⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML).

HY-153200

MDM2/XIAP-IN-2	MDM-2/p53	Cancer
MDM2/XIAP-IN-2 is a dual inhibitor of murine double minute 2 (MDM2) and X-linked inhibitor of apoptosis protein (XIAP). MDM2/XIAP-IN-2 degrades MDM2, and inhibits XIAP mRNA translation to inhibits cancer cells. Particularly, MDM2/XIAP-IN-2 inhibits acute lymphoblastic leukemia cell line EU-1 with an IC₅₀ value of 0.3 μM.

HY-112852A

TL02-59 dihydrochloride	Src Apoptosis	Cancer
TL02-59 dihydrochloride is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 dihydrochloride inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 dihydrochloride potently suppresses acute myelogenous leukemia (AML) cell growth.

HY-112852

TL02-59	Src Apoptosis	Cancer
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC₅₀ of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC₅₀s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth.

HY-144709

FLT3/ITD-IN-1	FLT3	Cancer
FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 38.2 nM and 144.1 nM against FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines.

HY-116830

BRD0705	GSK-3	Cancer
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC₅₀ of 66 nM and a K_d of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC₅₀ of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML) research.

HY-143434

FLT3/D835Y-IN-1	FLT3	Cancer
FLT3/D835Y-IN-1 (compound 13a) is a orally active, potent and selective FLT3 and FLT3/D835Y inhibitor, with IC₅₀ values of 0.26 nM and 0.18 nM, respectively. FLT3/D835Y-IN-1 also blocks tumor growth, has anticancer efficacy, and can be used to research for AML (acute myeloid leukemia).

HY-P99412

Lusvertikimab OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research.

HY-P99255

Moxetumomab pasudotox CAT 8015; HA 22; Anti-Human CD22 Recombinant Antibody	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL).

HY-106218

Flurocitabine 5-Fluorocyclocytidine; 5'-Fluorocyclocytidine	Nucleoside Antimetabolite/Analog	Cancer
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors.

HY-129079A

TFMB-(S)-2-HG	DNA Methyltransferase	Cancer
TFMB-(S)-2-HG is a potent inhibitor of the 5'-methylcytosine hydroxylase TET2. TFMB-(S)-2-HG also inhibits the EglN prolyl hydroxylases. TFMB-(S)-2-HG has the potential for the research of acute myeloid leukemia (AML).

HY-N7634

Tectol	Farnesyl Transferase Parasite	Cancer Infection
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM. Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM.

HY-114989

Fluorizoline	Apoptosis	Cancer
Fluorizoline selectively and directly binds to prohibitin 1 (PHB1) and 2 (PHB2), and induces apoptosis. Fluorizoline reduces chronic lymphocytic leukemia (CLL) cell viability through the upregulation of NOXA and BIM. Fluorizoline exerts antitumor action in a p53-independent manner.

HY-143247

Tubulin polymerization-IN-2	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-2 is a potent anticancer agent targeting to β-tubulin with an IC₅₀ value of 0.92 μM. Tubulin polymerization-IN-2 shows promising activity against various leukemia, non-small lung, renal, prostate, and breast cancer cell lines.

HY-136291

Sulfo-SPDB-DGN462	Drug-Linker Conjugates for ADC	Cancer
Sulfo-SPDB-DGN462 is a agent-linker conjugate for ADC. Sulfo-SPDB-DGN462 consists a toxin DGN462 (HY-101150) conjugated to the cleavable Sulfo-SPDB linker. DGN462, a potent?DNA-alkylating?agent, shows anti-tumor activity, such as acute myeloid leukemia (AML).

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

HY-151902

SJ988497	PROTACs JAK	Cancer
SJ988497 is a PROTAC JAK2 degrader. SJ988497 potently inhibits CRLF2-rearranged (CRLF2r) cell proliferation and degrades the CRBN neosubstrate GSPT1. SJ988497 consists of a Ruxolitinib (HY-50856) derivative, linker, and CRBN ligand Pomalidomide. SJ988497 can be used in the research of acute lymphoblastic leukemia (ALL).

HY-147900

PI3K-IN-35	PI3K Apoptosis	Cancer
PI3K-IN-35 (Compound 6l) is a highly selective PI3K inhibitor with IC₅₀ values of 13.98, 7.22 and 10.94 μM for PI3K-α、PI3K-β and PI3K-δ, respectively. PI3K-IN-35 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-35 can be used in leukemia research.

HY-147898

PI3K-IN-33	PI3K Apoptosis	Cancer
PI3K-IN-33 (Compound 6e) is a highly selective PI3K inhibitor with IC₅₀ values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-33 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-33 can be used in leukemia research.

HY-147899

PI3K-IN-34	PI3K Apoptosis	Cancer
PI3K-IN-34 (Compound 6g) is a highly selective PI3K inhibitor with IC₅₀ values of 11.73, 6.09 and 11.18 μM for PI3K-α、PI3K-β and PI3K-δ , respectively. PI3K-IN-34 arrests cell cycle at G2/M phase and induces apoptosis. PI3K-IN-34 can be used in leukemia research.

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.

HY-132189

Laniquidar R101933	P-glycoprotein	Cancer
Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC₅₀ of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Laniquidar has limited oral bioavailability.

HY-142690

HDAC-IN-27	HDAC	Cancer
HDAC-IN-27 (Compound 11h) is a potent, selective and orally active HDAC Class I inhibitor, with IC₅₀ values ranging from 0.43 nM to 3.01 nM for HDAC1-3. HDAC-IN-27 shows anti-acute myeloid leukemia (AML) activity.

HY-144711

FLT3/ITD-IN-3	FLT3	Cancer
FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 0.9 nM against FLT3^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines.

HY-144710

FLT3/ITD-IN-2	FLT3	Cancer
FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC₅₀ values of 0.3, 0.4 and 1.0 nM against FLT3^D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines.

HY-16271

Kevetrin hydrochloride 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells.

HY-10202A

Tandutinib hydrochloride MLN518 hydrochloride; CT53518 hydrochloride	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier.

HY-10202

Tandutinib MLN518; CT53518	FLT3 c-Kit PDGFR Apoptosis	Cancer
Tandutinib (MLN518) is a potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML). Tandutinib has the ability to cross the blood-brain barrier.

HY-13591

Piclidenoson IB-MECA; CF-101	Adenosine Receptor Apoptosis	Cancer Inflammation/Immunology
Piclidenoson (IB-MECA) is a first-in-class, orally active and selective A3 adenosine receptor (A3AR) agonist. Piclidenoson exhibits antiproliferative effect and induces apoptosis in different cancer cell types like melanoma, leukemia. Piclidenoson can be used for the research of autoimmune inflammatory diseases and COVID-19.

HY-141429C

AS-99	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-141429

AS-99 free base	Histone Methyltransferase Apoptosis	Cancer
AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Apoptosis	Cancer
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.

HY-P1923

L-Asparaginase L-ASNase	Apoptosis DNA/RNA Synthesis	Cancer
L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis.

HY-139481

TL-895	Btk	Cancer Infection
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC₅₀ and a K_i of 1.5 nM and 11.9 nM, respectively. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research.

HY-112328

Fascaplysin	Apoptosis Autophagy Reactive Oxygen Species	Cancer Infection
Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield). Fascaplysin can induces apoptosis and autophagy in human leukemia HL-60 cells. Fascaplysin shows anti-tumor activity.

HY-150797

QA-68 QA-68-ZU81	Epigenetic Reader Domain	Cancer Inflammation/Immunology
QA-68 (QA-68-ZU81) is a potent bromodomain-containing protein 9 (BRD9) degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines.

HY-12908

Bcl-xL antagonist 2	Bcl-2 Family Apoptosis	Cancer
Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-X_L with an IC₅₀ and K_i of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).

HY-113200

N1-Acetylspermine
Endogenous Metabolite Cancer

N1-Acetylspermine is an endogenous metabolite present in Urine that can be used for the research of Leukemia.

HY-144094

EZH2-IN-9	Histone Methyltransferase	Cancer
EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17).

HY-143616

EZH2-IN-7	Histone Methyltransferase	Cancer
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259).

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability.

HY-108350

MI-2-2	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation.

HY-15738

GNF-5	Bcr-Abl	Cancer
GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC₅₀ value of 0.22 µM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer.

HY-15255

Zosuquidar RS 33295-198; LY-335979	P-glycoprotein	Cancer
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.

HY-50671

Zosuquidar trihydrochloride RS 33295-198 trihydrochloride; LY-335979 trihydrochloride	P-glycoprotein	Cancer
Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (K_i=59 nM). Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.

HY-N0117

Indirubin Couroupitine B; Indigo red; Indigopurpurin	Apoptosis	Cancer
Indirubin (Couroupitine B) is a bis-indole alkaloid and has emarkable anticancer activity against chronic myelocytic leukemia.

HY-128347

M‑89	Epigenetic Reader Domain	Cancer Inflammation/Immunology
M-89 is a highly potent and specific menin inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the *menin-mixed lineage leukemia* (Menin-MLL) protein-protein interaction** and has potential to treat MLL leukemia.

HY-148530

YX-2-107	PROTACs CDK	Cancer
YX-2-107 is a PROTAC (IC₅₀= 4.4 nM) that selectively degrades CDK6. YX-2-107 effectively inhibits RB phosphorylation and FOXM1 expression in vitro and inhibits the development of Ph⁺ ALL in rats. YX-2-107 can be used in the study of Ph chromosome-positive (Ph⁺) acute lymphoblastic leukemia (ALL).

HY-136523

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells.

HY-12333

Denfivontinib G-749	FLT3 Apoptosis	Cancer
Denfivontinib (G-749) is a potent, oral active and ATP competitive FLT3 inhibitor, with IC₅₀s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML).

HY-146680

FLT3/ITD-IN-4	FLT3 RET CDK MAP4K	Cancer
FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC₅₀ of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research.

HY-143894

FLT3-IN-11	FLT3	Cancer
FLT3-IN-11 (compound 30) is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 7.22 nM and 4.95 nM for wild-type FLT3 and FLT3-D835Y, respectively. FLT3-IN-11 high selectivity for FLT3 over c-KIT (>1000-fold). FLT3-IN-11has excellent anti-acute myeloid leukemia (AML) activity (MV4-11 cells, IC₅₀ of 3.2 nM).

HY-115463

EB-3D	AMPK Apoptosis	Cancer
EB-3D is a potent and selective choline kinase α (ChoKα) inhibitor, with an IC₅₀ of 1 μM for ChoKα1. EB-3D exerts effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum stress and lipid metabolism. EB-3D exhibits a potent antiproliferative activity in a panel of T-leukemia cell lines. Anti-cancer activity.

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines.

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines.

HY-124822

COH-SR4	AMPK	Cancer Metabolic Disease
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.

HY-120035

DD1	Proteasome Ribosomal S6 Kinase (RSK) Apoptosis	Cancer
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation.

HY-147574

Axl-IN-7	TAM Receptor	Cancer Inflammation/Immunology Cardiovascular Disease
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba⁄F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML).

HY-145550

Amredobresib BI894999	Epigenetic Reader Domain	Cancer
Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1).

HY-12279

Umbralisib TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach.

HY-17600

Acalabrutinib ACP-196	Btk	Cancer
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

HY-108263B

(R)-3-Hydroxy Midostaurin (R)-CGP52421	FLT3 Drug Metabolite	Cancer
(R)-3-Hydroxy Midostaurin ((R)-CGP52421) is a potent kinases inhibitor. (R)-3-Hydroxy Midostaurin is a major metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (R)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).

HY-118304

AKN-028	FLT3 Apoptosis Caspase	Cancer
AKN-028, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC₅₀ value of 6 nM. AKN-028 inhibits FLT3 autophosphorylation. AKN-028 induces dose-dependent cytotoxic response (mean IC₅₀=1 μM). AKN-028 induces apoptosisby activation of caspase 3. AKN-028 can be used in research of acute myeloid leukemia (AML).

HY-12892

SKI-178	SphK Apoptosis	Cancer
SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC₅₀ concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines.

HY-118304B

AKN-028 acetate	FLT3 Apoptosis Caspase	Cancer
AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC₅₀ value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN-028 acetate induces dose-dependent cytotoxic response (mean IC₅₀=1 μM). AKN-028 acetate induces apoptosisby activation of caspase 3. AKN-028 acetate can be used in research of acute myeloid leukemia (AML).

HY-15650

SGC0946	Histone Methyltransferase	Cancer
SGC0946 is a selective DOT1LH3K79 methyltransferase) inhibitor, with an IC₅₀ of 0.3 nM. SGC0946 results in G1 arrest, inhibits potential of cell self-renewal and metastatic, also induces cell differentiation. SGC0946 can be used in studies of leukemia and solid tumors and also serve as a probe to further investigate the cellular mechanism of DOT1L in both normal and diseased cells.

HY-138295

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1.

HY-150507

JNJ-4355
Bcl-2 Family Cancer

JNJ-4355 is a highly potent MCL-1 (myeloid cell leukemia-1) inhibitor, with K_I of 18 pM. JNJ-4355 shows antitumor activity.

HY-108603

Bryostatin 2 (+)-Bryostatin 2	Others	Cancer
Bryostatin 2 ((+)-Bryostatin 2) is a 20-membered ring lactone that can be found in Bryozoan Eugufa neritina L. Bryostatin 2 has the potential for the research of P-388 lymphocytic leukemia.

HY-12279B

Umbralisib sulfate TGR-1202 sulfate; RP-5264 sulfate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach.

HY-100949

EC330
Others Cancer

EC330 is a leukemia inhibitory factor (LIF) inhibitor.
HY-128571

FLT3-IN-4
FLT3 Cancer

FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC₅₀=7 nM) inhibitor for treating acute myelogenous leukemia.

HY-147298

Plogosertib CYC140	Polo-like Kinase (PLK)	Cancer
Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC₅₀: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers.

HY-N0990

1,5,15-Trimethylmorindol	Others	Cancer
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay.

HY-128607

Mcl1-IN-9
Bcl-2 Family Cancer

Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC₅₀ of 446 nM in reengineered BCR-ABL+ B-ALL cells and a K_i of 0.03 nM.

HY-148422

Rohinitib	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML.

HY-13062A

Daunorubicin Daunomycin; RP 13057; Rubidomycin	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis	Cancer Infection Neurological Disease
Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

HY-13062

Daunorubicin hydrochloride Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Bacterial Autophagy Apoptosis Antibiotic	Cancer Infection Neurological Disease
Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

HY-114410

CCI-006	Mitochondrial Metabolism	Cancer
CCI-006 is a selective inhibitor and chemosensitizer of MLL-rearranged leukemia cells, by inhibits mitochondrial respiration resulting in insurmountable mitochondrial depolarization and a pro-apoptotic unfolded protein response (UPR) in a subset of MLL-r leukemia cells.

HY-129239

Farudodstat ASLAN003	Dihydroorotate Dehydrogenase DNA/RNA Synthesis Apoptosis	Cancer
Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC₅₀ of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice.

HY-136351

THZ-P1-2	Autophagy	Cancer
THZ-P1-2 is a first-in-class and selective PI5P4K inhibitor, with an IC₅₀ of 190 nM for PI5P4Kα. THZ-P1-2 covalently targets cysteines on a disordered loop in PI5P4Kα/β/γ. THZ-P1-2 causes autophagy disruption and upregulates TFEB signaling. THZ-P1-2 displays anticancer activity in leukemia cell lines.

HY-108263A

(S)-3-Hydroxy Midostaurin (S)-CGP52421	FLT3 Drug Metabolite	Cancer
(S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with IC₅₀ values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et). (S)-3-Hydroxy Midostaurin is a minor metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (S)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).

HY-120877

MRT199665	Salt-inducible Kinase (SIK) AMPK Apoptosis	Cancer
MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC₅₀s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370.

HY-12279C

Umbralisib hydrochloride TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach.

HY-12279A

Umbralisib tosylate TGR-1202 tosylate; RP5264 tosylate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach.

HY-108876

Daunorubicin citrate Daunomycin(citrate); RP 13057(citrate); Rubidomycin(citrate)	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis	Cancer Infection Neurological Disease
Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

HY-115906

K783-0308	FLT3 MNK Apoptosis	Cancer
K783-0308 is a potent and selective dual inhibitor of FLT3 and MNK2 with IC₅₀ values of 680 and 406 nM, respectively. K783-0308 inhibits the growth of MOLM-13 (IC₅₀=10.5 µM) and MV-4-11 (IC₅₀=10.4 µM) cells. K783-0308 promotes acute myeloid leukemia (AML) cell apoptosis and cell cycle arrests in the G0/G1 phase.

HY-13641

Mitobronitol Myelobromol; DBM	DNA Alkylator/Crosslinker	Cancer
Mitobronitol (Myelobromol; DBM) is a brominated analog of mannitol, also known as an anticancer agent that is classified as an alkylating agent. Mitobronitol has potential for myelosuppression associated with significantly decreased risk for several complications of allogeneic bone marrow transplantation in accelerated chronic granulocytic leukemia.

HY-147330

SJ1008030	PROTACs JAK	Cancer
SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades JAK2. SJ1008030 inhibits MHH–CALL-4 cells with an EC₅₀ of 5.4 nM and an IC₅₀ of 32.09 nM. SJ1008030 can be used for the research of leukemia.

HY-14518

Aminopterin 4-Aminofolic acid; APGA	Antifolate	Cancer Inflammation/Immunology
Aminopterin (4-Aminofolic acid), the 4-amino derivative of folic acid, is a folic acid antagonist. Aminopterin catalyses the reduction of folic acid to tetrahydrofolic acid, and competitively inhibits dihydrofolate reductase (DHFR) with a K_i of 3.7 pM. Aminopterin has anticancer and immunosuppressive activity. Aminopterin is used in treatment of pediatric leukemia.

HY-126143

CHMFL-ABL-039	Bcr-Abl	Cancer
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC₅₀s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia.

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL).

HY-142696

CDK6/PIM1-IN-1	CDK Pim Apoptosis	Cancer
CDK6/PIM1-IN-1 is a potent and balanced dual CDK6/PIM1 inhibitor with IC₅₀ values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC₅₀=3.6 nM). CDK6/PIM1-IN-1 significantly inhibits acute myeloid leukemia (AML) cell proliferation, arrest cell cycle at the G1 phase, and promote cell apoptosis. CDK6/PIM1-IN-1 exhibits potent anti-AML activity.

HY-N10591

Bruceantarin
Others Cancer

Bruceantarin is a potent antineoplastic agent. Bruceantarin can be used for leukemia and breast cancer research.

HY-150025

(4aS,8aR)-NPD-001	DNA Methyltransferase Apoptosis	Cancer
(4aS,8aR)-NPD-001 is a potent and allosteric inhibitor of DNMT3A. (4aS,8aR)-NPD-001 inhibits DNMT3A activity by disrupting protein-protein interactions. (4aS,8aR)-NPD-001 induces apoptosis of acute myeloid leukemia (AML) cell lines. (4aS,8aR)-NPD-001 induces differentiation of distinct AML cell lines including cells with mutated DNMT3A R882.

HY-124069

M-525	Epigenetic Reader Domain	Cancer
M-525 is a first-in-class, highly potent, irreversible and covalent menin-MLL protein-protein interaction inhibitor. M-525 binds to menin with an IC₅₀ of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity.

HY-139877

OXS007417
Others Cancer

OXS007417 induces differentiation of acute myeloid leukemia cells (EC₅₀ = 48 nM) in vitro and shows antitumor effects in vivo.
HY-N2517

Dihydroevocarpine
mTOR Cancer

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity.

HY-128888B

(S,R)-GSK321	Isocitrate Dehydrogenase (IDH)	Cancer
(S,R)-WT IDH1 Inhibitor 2 (GSK321) is a potent, selective mutant IDH1 inhibitor with IC₅₀ values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-WT IDH1 Inhibitor 2 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-WT IDH1 Inhibitor 2 can be used for research of acute myeloid leukemia (AML) and other cancers.

HY-132969

SBP-3264
Others Cancer

SBP-3264 is a valuable chemical probe for understanding the roles of STK3 and STK4 in acute myeloid leukemia (AML).

HY-14572

PR-104A SN 27858	DNA Alkylator/Crosslinker Drug Metabolite	Cancer
PR-104A (SN 27858) is the alcohol metabolite of phosphate proagent PR-104. PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity. PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase. PR-104A can be used for the research of relapsed/refractory T-lineage acute lymphoblastic leukemia (T-ALL).

HY-14519S

Methotrexate-d3	Antifolate DNA/RNA Synthesis ADC Cytotoxin Apoptosis	Cancer Inflammation/Immunology
Methotrexate-d₃ (Amethopterin-d3) is the deuterium labeled Methotrexate. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice.

HY-146749

FLT3/TrKA-IN-1	FLT3 Trk Receptor Apoptosis	Cancer
FLT3/TrKA-IN-1 is a potent FLT3/TrKA dual kinase inhibitor with the IC₅₀s of 43.8 nM, 97.2 nM, 92.5 nM and 23.6 nM for FLT3, FLT3-ITD, FLT3-TKD and TrKA, respectively. FLT3/TrKA-IN-1 induces cell cycle arrest at the G0/G1 phase as well as apoptosis and shows antiproliferative activity in vitro. FLT3/TrKA-IN-1 has the potential for the research of Acute myeloid leukemia (AML).

HY-150725

ODN 1585	IFNAR TNF Receptor	Cancer Infection Inflammation/Immunology
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant.

HY-144835

FHD-286
Epigenetic Reader Domain Cancer

FHD-286 is a BRG1/BRM ATPase inhibitor for the research of BAF-related disorders such as acute myeloid leukemia.

HY-108315

6-Aminochrysene 6-Chrysenamine	Others	Cancer Inflammation/Immunology
6-Aminochrysene (6-Aminochrysene) is an aromatic amine used as a chemotherapeutic agent in the treatment of splenomegaly, myeloid leukemia, and breast cancer.

HY-18714

BRD7116
Bacterial Others

BRD7116 competitively binds to bacterial DNA gyrase, exhibits an EC50 of 200 nM for LSCe cells, with cell-non-autonomous anti-leukemia activity.
HY-100741

S63845
Bcl-2 Family Cancer

S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a K_d of 0.19 nM for human MCL1.

HY-13701

Nelarabine 506U78; GW 506U78; Nelzarabine	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL).

HY-N6733

Aphidicolin	DNA/RNA Synthesis HSV Apoptosis Antibiotic Orthopoxvirus	Infection Inflammation/Immunology
Aphidicolin is an inhibitor of DNA polymerase α and δ, prevents mitotic cell division by interfering DNA polymerase activity. Aphidicolin is an antibiotic produced by mold Cephalosporium aphidicola, inhibits cellular deoxyribonucleic acid synthesis and the growth of herpes simplex virus. Aphidicolin exhibits anti-orthopoxvirus activity and potentiates apoptosis induced by arabinosyl nucleosides in a human promyelocytic leukemia cell line.

HY-13560

AVN-944 VX-944	Arenavirus DNA/RNA Synthesis Apoptosis Caspase Bcl-2 Family	Cancer Infection
AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research.

HY-125908

A-1210477-piperazinyl PROTAC Mcl1-binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
A-1210477-piperazinyl is a compound binds to protein myeloid cell leukemia 1 (MCL1) used for PROTAC technology.

HY-100314

BCR-ABL-IN-1
Bcr-Abl Cancer

BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC₅₀ of 6.46, and may be used in the research of chronic myelogenous leukemia.

HY-B1751C

Quinine hydrobromide	Parasite Cytochrome P450 Potassium Channel	Infection
Quinidine hydrobromide is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine hydrobromide is also a K⁺ channel blocker with an IC₅₀ of 19.9 μM. Quinidine hydrobromide can be used for malaria research.

HY-B1751B

Quinine sulfate	Parasite Potassium Channel Cytochrome P450	Cancer Infection Cardiovascular Disease
Quinidine is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine is also a K⁺ channel blocker with an IC₅₀ of 19.9 μM. Quinidine can be used for malaria research.

HY-125136

Chaetominine (-)-Chaetominine	PI3K Akt Keap1-Nrf2	Cancer
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells.

HY-19356

Rocaglamide Roc-A	NF-κB HSP Eukaryotic Initiation Factor (eIF)	Cancer
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

HY-15229

Guadecitabine sodium SGI-110 sodium; S-110 sodium	DNA Methyltransferase	Cancer
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

HY-13542

Guadecitabine SGI-110	DNA Methyltransferase	Cancer
Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

HY-N5007

Galgravin	Apoptosis	Cancer
Galgravin is an active compound in Nectandra megapotamica, with anti-inflammatory activity. Galgravin displays in vitro cytotoxic activity and induce apoptosis in leukemia cells.

HY-N6037

Gardenin B
Apoptosis Cancer

Gardenin B is a flavonoid isolated from Gardenia jasminoides. Gardenin B induces cell death in human leukemia cells involves multiple caspases.

HY-13072

Cenisertib AS-703569; R-763	Aurora Kinase Bcr-Abl Akt STAT FLT3	Cancer
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.

HY-150569

BCR-ABL-IN-6	Bcr-Abl	Cancer
BCR-ABL-IN-6 (9h) is a selective Bcr-Abl kinase inhibitor with IC₅₀s of 4.6 and 227 nM for Bcr-Abl^WT and Bcr-Abl^T3151 respectively. BCR-ABL-IN-6 inhibits Bcr-Abl kinase with strong affinity inside the cells with an EC₅₀ of 14.6 nM. BCR-ABL-IN-6 is an imatinib derivative which can be used for research of chronic myelogenous leukemia.

HY-142102

T988C
(+)-T988C
Others Cancer

T988C is a heptacyclic epidithiodioxopiperazine (ETP) natural product. T988C shows strong cytotoxicity to cultured P388 leukemia cells.

HY-19541A

I-CBP112 hydrochloride	Epigenetic Reader Domain	Cancer
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (K_ds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin.

HY-143286

PF15	PROTACs FLT3	Cancer
PF15 is a PROTAC connected by ligands for FLT3 kinase and CRBN. PF15 is a high selective FLT3-ITD degrader, with a DC₅₀ of 76.7 nM. PF15 significantly inhibits the proliferation of FLT3-ITD-positive cells, can down-regulate the phosphorylation of FLT3 and STAT5. PF15 also inhibits tumor growth in mouse models and can be used in study of leukemia.

HY-122698

CCI-007
Apoptosis Cancer

CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC₅₀ values of 2.5-6.2 μM in sensitive cells.

HY-148669

Menin-MLL inhibitor 24	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 24 (compound A) is a *menin-mixed-lineage leukemia* 1 (menin-MLL)** inhibitor. Menin-MLL inhibitor 24 can be used for the research of cancer.

HY-N3308

Medicarpin	Apoptosis	Cancer
Medicarpin is a flavonoid isolated from Medicago sativa. Medicarpin induces apoptosis and overcome multidrug resistance in leukemia P388 cells by modulating P-gp-mediated efflux of agents.

HY-N2732

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Others	Cancer
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells.

HY-12459

Pyrindamycin B	Bacterial	Infection
Pyrindamycin B is an antibiotic, actives against gram-positive and gram-negative bacterias, and exhibits strong therapeutic effects against both agent-sensitive and resistant cells of P388 leukemia in mice.

HY-N6017

Bakkenolide A	HDAC	Cancer
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.

HY-N8390

3-Epidehydropachymic acid	Others	Cancer
3-Epidehydropachymic acid, a lanostane triterpenoid, shows totoxicity effect against human acute monocytic leukemia cell line THP-1 (IC₅₀=52.51 μM).

HY-33350

Clofilium tosylate	Potassium Channel Apoptosis	Cancer Cardiovascular Disease
Clofilium tosylate, a potassium channel blocker, induces apoptosis of human promyelocytic leukemia (HL-60) cells via Bcl-2-insensitive activation of caspase-3. Antiarrhythmic agent.

HY-146809

Galectin-3 antagonist 2	Galectin	Cancer
Galectin-3 is a β Galactoside specific carbohydrate recognition protein (lectin) has the ability to promote the migration of B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug research.

HY-141703

DC-BPi-11	Epigenetic Reader Domain	Cancer
DC-BPi-11 is an inhibitor of bromodomain PHD finger transcription factor (BPTF), with an IC₅₀ value of 698 nM. DC-BPi-11 shows remarkable inhibition against leukemia cell proliferation.

HY-126193

JS-K	NO Synthase Apoptosis	Cancer
JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH. JS-K inhibits proliferation, induces apoptosis, and disrupts the cell cycle of Jurkat T acute lymphoblastic leukemia cells.

HY-120142

EC359	Apoptosis	Cancer
EC359 is a potent, selective, high affinity and orally active leukemia inhibitory factor receptor (LIFR) inhibitor with a K_d of 10.2 nM, which directly interacts with LIFR to effectively block LIF/LIFR interactions.

HY-U00442

CTX1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.

HY-108704

CT-721	Bcr-Abl	Cancer
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC₅₀ of 21.3 nM for wild-type Bcr-Abl kinase, and possesses anti-chronic myeloid leukemia (CML) activities.

HY-122562

MT-802	PROTACs Btk	Cancer Inflammation/Immunology
MT-802 is a potent BTK degrader based on Cereblon ligand, with a DC₅₀ of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).

HY-N0840

Bruceantin (-)-Bruceantin; NCI165563; NSC165563	Others	Cancer
Bruceantin(NSC165563) is first isolated from Brucea javanica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice.

HY-N2108

7-Ethylcamptothecin	Others	Cancer
7-Ethylcamptothecin is one of camptothecin analogues. camptothecin (CPT), a cytotoxic alkaloid isolated from Camptotheca acuminata, is shown to have strong antitumor activity against L1210 leukemia and Walker 256 carcinosarcoma models.

HY-N0488A

Vincristine Leurocristine; NSC-67574; 22-Oxovincaleukoblastine	Microtubule/Tubulin Antibiotic	Cancer
Vincristine (Leurocristine) is a microtubule-destabilizing agent (MDA). Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine is used to research hematologic cancers, such as leukemia and lymphoma, and childhood sarcomas.

HY-132231

FD223	PI3K Apoptosis	Cancer
FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC₅₀=1 nM) and good selectivity over other isoforms (IC₅₀s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML.

HY-12757

YHO-13177	BCRP	Cancer
YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells.

HY-148203

Mcl-1 inhibitor 9	Bcl-2 Family	Cancer
Mcl-1 inhibitor 9 (example 2) is a *myeloid cell leukemia* 1 (Mcl-1) inhibitor with IC₅₀** value of 0.21889 nM. Mcl-1 inhibitor 9 shows anti-tumor activity.

HY-P2267

LDV
Integrin Others

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells.

HY-106014

Tezacitabine	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Tezacitabine is a cytostatic and cytotoxic antimetabolite and a nucleoside analogue. Tezacitabine irreversibly inhibits the ribonucleotide reductase and interferes with DNA replication and repair. Tezacitabine effectively induces cells apoptotic. Tezacitabine has the potential for leukemias and solid tumors (carcinomas) treatment.

HY-102048

STAT5-IN-2
STAT Apoptosis Cancer

STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect.
HY-132199

SJ6986
Others Cancer

SJ6986 is a potent, selective and orally active GSPT1/2 degrader, with a DC₅₀ of 2.1 nM (D_max 99%) for GSPT1.
HY-108277

Ginsenoside F5
Apoptosis Cancer

Ginsenoside F5, from crude extracts of flower buds of Panax ginseng, remarkably inhibits the growth of HL-60 cells by the apoptosis pathway.

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Cancer Infection Inflammation/Immunology
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-P1785

Abl Cytosolic Substrate	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus.

HY-123954

Casein Kinase inhibitor A51	Casein Kinase CDK Apoptosis	Cancer
Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities.

HY-150586

PTG-0861	HDAC Apoptosis	Cancer
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC₅₀ value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers.

HY-N8593

Undecane	TNF Receptor	Infection
Undecane has anti-allergic and anti-inflammatory activities on sensitized rat basophilic leukemia (RBL-2H3) mast cells and HaCaT keratinocytes. In sensitized mast cells, Undecane inhibits degranulation and the secretion of histamine and TNF-α^[

HY-112316

BAY1238097	Epigenetic Reader Domain	Cancer
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC₅₀ <100 nM).

HY-13593

Chlorambucil CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease.

HY-16782

Pexmetinib ARRY-614	p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-N0071

Crotonoside Isoguanosine	FLT3 HDAC	Cancer
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML.

HY-12445

Asnuciclib CDKI-73; LS-007	CDK Apoptosis	Cancer Inflammation/Immunology
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious CDK9 inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion.

HY-N3584

Paris saponin VII Chonglou Saponin VII	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis	Cancer
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.

HY-127130

Spicamycin	Bcl-2 Family Apoptosis Fungal Antibiotic	Cancer Infection
Spicamycin, an adenine nucleoside antibiotic with antifungal and antitumor activities. Spicamycin is also a potent inducer of differentiation of myeloid leukemia cells. Spicamycin induces apoptosis in NB4 cells via down-regulation of Bcl-2 expression and modulation of PML protein.

HY-100688

ML390	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models.

HY-111249

TTT 3002	FLT3	Cancer
TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC₅₀ of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research.

HY-N11370

Mesobuthus Eupeus Venom Lesser Asian scorpion Venom	Others	Cancer
Mesobuthus Eupeus Venom (Lesser Asian scorpion Venom) is a scorpion venom that can be obtained from Lesser Asian scorpion. Mesobuthus Eupeus Venom induces selective toxicity in chronic lymphocytic leukemia B-lymphocytes through lysosomal/mitochondrial dysfunction and reactive oxygen species formation.

HY-125098

Illudin S	DNA Alkylator/Crosslinker Apoptosis	Cancer Infection
Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells.

HY-13297

PYZD-4409	E1/E2/E3 Enzyme	Cancer
PYZD-4409 is a specific inhibitor of the ubiquitin-activating enzyme UBA1 with an IC₅₀ of 20 μM (cell-free enzymatic assay). PYZD-4409 induces cell death in malignant cells and preferentially inhibits the clonogenic growth of primary acute myeloid leukemia cells.

HY-14942A

RTA 744 WP 744; WP 769 hydrochloride; Berubicin hydrochloride	Apoptosis	Cancer
RTA 744 (WP 744) is a Doxorubicin (HY-15142A) analogue. RTA 744 triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. RTA 744 has proapoptotic and anti-leukemia activities. RTA 744 can be used for cancer research.

HY-139193

TH1760	Others	Cancer
TH1760 is an inhibitor of NUDIX-type 15 (NUDT15) with an IC₅₀ value of 25 nM. TH1760 sensitizes cells to 6-thioguanine by enhancing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 enhances the anti-leukemia effect of thiopurine.

HY-122529

Almurtide	Bacterial	Infection
Almurtide (nor-MDP), a muramyl dipeptide derivative with anti-inflammatory and anti-tumor activity. Almurtide also shows protective effects against intraperitoneal Pseudomonas aeruginosa infection or intravenously Candida albicans infection in mice. Almurtide also inhibits the carcinogenic Friend leukemia virus.

HY-N8098

Pulchinenoside E2	Others	Cancer
Pulchinenoside E2 (Compound 8) is a triterpene saponin isolated from the roots of Pulsatilla chinensis. Pulchinenoside E2 shows cytotoxic to HL-60 cells with an IC₅₀ value of 2.6 µg/mL.

HY-133738

M-808
Epigenetic Reader Domain Cancer

M-808 is a highly potent and efficacious covalent Menin-MLL interaction inhibitor, with a binding IC₅₀ value of 2.6 nM.
HY-105270

Tallimustine
FCE 24517
Others Cancer

Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent.

HY-147934

HDAC8-IN-3	HDAC Apoptosis	Cancer
HDAC8-IN-3 (compound P19) is a potent HDAC8 inhibitor with IC₅₀ value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines.

HY-12214A

NVP-2	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 µM, 0.706 µM, and 0.605 µM, respectively. NVP-2 induces cell apoptosis.

HY-135145

CB-103	Notch	Cancer
CB-103 is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. CB-103 has anti-tumor activity.

HY-111976

MT1
Epigenetic Reader Domain Cancer

MT1 is a bivalent chemical probe of BET bromodomains, with an IC₅₀ of 0.789 nM for BRD4(1).

HY-109108A

Valemetostat tosylate DS-3201 tosylate	Histone Methyltransferase	Cancer
Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma.

HY-139147

iHCK-37 ASN05260065	Src	Cancer Infection
iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a K_i value of 0.22 μM. iHCK-37 blocks HIV-1 viral replication with an EC₅₀ value of 12.9 μM. iHCK-37 is used for chronic myeloid leukemia (CML) research.

HY-134978A

(+)SHIN2	Others	Cancer
(+)SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor, whose target can be traced with ¹³C-serine. (+)SHIN2 increases survival in NOTCH1-driven mouse primary acute lymphoblastic leukemia (T-ALL) in vivo with a synergistic effect with Methotrexate (HY-14519).

HY-112052

Aminomalonic acid	Endogenous Metabolite	Cancer
Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (K_i= 0.0023 M) and mouse pancreas (K_i= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis.

HY-120075

TJ191	Apoptosis	Cancer
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research.

HY-128360

dMCL1-2	PROTACs Bcl-2 Family Apoptosis	Cancer
dMCL1-2 is a potent and selective PROTAC of *myeloid cell leukemia* 1 (MCL1) (Bcl-2 family member) based on Cereblon, which binds to MCL1 with a K_D** of 30 nM. dMCL1-2 activats the cellular apoptosis machinery by degradation of MCL1.

HY-N2492

(E)-Methyl 4-coumarate Methyl trans-p-coumarate	Bacterial Apoptosis	Cancer Infection
(E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-13593S

Chlorambucil-d8 CB-1348-d₈; WR-139013-d₈	DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈ is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-110113

CTA056	Btk	Cancer
CTA056 is an ITK (IL-2-inducible T-cell kinase) inhibitor with an IC₅₀ of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the research of T-cell leukemia and lymphoma.

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research.

HY-124573

OBI-3424 TH-3424	DNA Alkylator/Crosslinker	Cancer
OBI-3424 (TH-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. OBI-3424 can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research.

HY-100869

MM-589	Histone Methyltransferase	Cancer
MM-589 is a potent inhibitor of *WD repeat domain 5 (WDR5) and mixed lineage leukemia* (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC₅₀ of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC₅₀** of 12.7 nM.

HY-139181

NR160	HDAC	Cancer
NR160 is a selective HDAC6 inhibitor with an IC₅₀ value of 30 nM. NR160 shows low cytotoxicity against leukemia cell line. NR160 augments the apoptosis induction of Bortezomib (HY-10227) (proteasome inhibitor), Epirubicin (HY-13624) and Daunorubicin (HY-13062A) significantly.

HY-149009

Bcl-2-IN-9	Bcl-2 Family Apoptosis	Cancer
Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC₅₀ value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells.

HY-N10777

1-Ketoaethiopinone	Others	Cancer
1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma).

HY-129079

TFMB-(R)-2-HG	Others	Cancer
TFMB-(R)-2-HG, a cell membrane-permeable version of (R)-2-HG, is a carcinogenic factor in Acute myeloid leukemia (AML). TFMB-(R)-2-HG impairs SCF ER-Hoxb8 cells differentiation in response to estrogen withdrawal.

HY-N2435

[8]-Shogaol	COX Apoptosis	Cancer
[8]-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity (IC₅₀=5 μM) and inhibits COX-2 (IC₅₀=17.5 μM). [8]-Shogaol induces apoptosis in human leukemia cells.

HY-13593S1

Chlorambucil-d8-1 CB-1348-d₈-1; WR-139013-d₈-1	DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-N8593S

Undecane-d24	TNF Receptor	Infection
Undecane-d₂₄ is the deuterium labeled Undecane[1]. Undecane has anti-allergic and anti-inflammatory activities on sensitized rat basophilic leukemia (RBL-2H3) mast cells and HaCaT keratinocytes. In sensitized mast cells, Undecane inhibits degranulation and the secretion of histamine and TNF-α[2].

HY-112037

IACS-010759 IACS-10759	Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research.

HY-100869A

MM-589 TFA	Histone Methyltransferase	Cancer
MM-589 TFA is a potent inhibitor of *WD repeat domain 5 (WDR5) and mixed lineage leukemia* (MLL) protein-protein interaction. MM-589 binds to WDR5 with an IC₅₀ of 0.90 nM and inhibits the MLL H3K4 methyltransferase activity with an IC₅₀** of 12.7 nM.

HY-112316A

(R)-BAY1238097	Epigenetic Reader Domain	Cancer
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome.

HY-13765

6-Thioguanine Thioguanine; 2-Amino-6-purinethiol	SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite	Cancer Infection Inflammation/Immunology
6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC₅₀s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

HY-12458

Pyrindamycin A	DNA/RNA Synthesis	Cancer Infection
Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC₅₀ of 3.9 μg/ml.

HY-153008

BCR-ABL-IN-7	Bcr-Abl	Cancer
BCR-ABL-IN-7 (compound 4) is a WT and T315I mutant ABL kinases inhibitor. BCR-ABL-IN-7 effectively inhibits activities of WT and T315I mutant ABL kinases. BCR-ABL-IN-7 can be used for the research of chronic myeloid leukemia (CML) research.

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

HY-117596

UNC569	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-P99253

Mogamulizumab KW-0761	CCR	Cancer Inflammation/Immunology
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).

HY-141429A

AS-99 TFA	Histone Methyltransferase Apoptosis	Cancer
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC₅₀= 0.79 µM, K_d= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.

HY-112037A

IACS-010759 hydrochloride IACS-10759 hydrochloride	Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research.

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

HY-N10350

2,3-Dihydro-3-methoxywithaferin A	Others	Cancer
2,3-Dihydro-3-methoxywithaferin A is an analogue of 2,3-dihydrowithaferin-A. 2,3-Dihydro-3-methoxywithaferin A inhibits proiiferation of P388 cells[1].

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.

HY-151366

HDAC8/BRPF1-IN-1	HDAC Epigenetic Reader Domain	Cancer
HDAC8/BRPF1-IN-1 (Compound 23a) is a dual inhibitor of HDAC8 and BRPF1 with an IC₅₀ of 443 nM against human HDAC8 and a K_d of 67 nM against human BRPF1. HDAC8/BRPF1-IN-1 shows low in vitro activity against HDAC1 and 6.

HY-12419

BMS-983970
Notch Cancer

BMS-983970 is an oral pan-Notch inhibitor for the treatment of multiplecancers.
HY-136546

Stafia-1
STAT Cancer

Stafia-1 is a potent STAT5a inhibitor (K_i=10.9 μM, IC₅₀=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.

HY-10127

Barasertib AZD1152	Aurora Kinase Apoptosis	Cancer
Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells.

HY-123159

AKI603	Aurora Kinase	Cancer
AKI603 is an inhibitor of Aurora kinase A (AurA), with an IC₅₀ of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.

HY-132001

Ziftomenib
KO-539
Epigenetic Reader Domain Cancer

Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).

HY-10126

Barasertib-HQPA AZD2811; INH-34; AZD1152-HQPA	Aurora Kinase Apoptosis	Cancer
Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.

HY-12649

Y16	Ras	Cancer
Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a K_d value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP.

HY-123955

Casein Kinase inhibitor A86	Casein Kinase CDK Apoptosis	Cancer
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities.

HY-16466

Spliceostatin A	Others	Cancer
Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells.

HY-152479

Topoisomerase IIα-IN-7	Topoisomerase	Cancer
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC₅₀ value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability.

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-N6736

K-252c	PKC Bacterial Apoptosis	Cancer Infection
K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC₅₀ of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.

HY-13905

Flumatinib mesylate HHGV678 mesylate	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC₅₀ values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model.

HY-114226

Olutasidenib FT-2102	Isocitrate Dehydrogenase (IDH)	Cancer Inflammation/Immunology
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC₅₀ values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .

HY-N2513

β-Boswellic acid	Lipoxygenase DNA/RNA Synthesis	Cancer
β-Boswellic acid is isolated from the gum resin of Boswellia serrata. β-Boswellic acid is a nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells.

HY-123905

LIN28 inhibitor LI71	MicroRNA	Cancer
LIN28 inhibitor LI71 is a potent and cell-permeable LIN28 inhibitor, which abolishes LIN28-mediated oligouridylation with an IC₅₀ of 7 uM. LIN28 inhibitor LI71 directly binds the cold shock domain (CSD) to suppress LIN28’s activity against let-7 in leukemia cells and embryonic stem cells.

HY-15166B

(E/Z)-Zotiraciclib citrate
(E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
CDK JAK FLT3 Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor.

HY-141430

AS-85	Histone Methyltransferase	Cancer
AS-85 is a potent ASH1L histone methyltransferase inhibitor (IC₅₀=0.6 µM) with anti-leukemic activity. AS-85 strongly binds to the ASH1L SET domain, with the K_d value of 0.78 µM.

HY-151404

Antitumor agent-76
Apoptosis Cancer

Antitumor agent-76 (Compound TP-P1) is an orally active, rapid-release and water-soluble Triptolide (HY-32735) proagent with antitumor activity.

HY-128798

Menin-MLL inhibitor 20	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6).

HY-N10189

Viridin
PI3K Endogenous Metabolite Cancer

Viridin is a secondary metabolite and naturally occurring furanosteroid. Viridin is potent inhibitor of the lipid kinase PI3K.

HY-117996

KPT-251	CRM1 Apoptosis	Cancer
KPT-251 is an orally active chromosome region maintenance 1 protein (CRM1) inhibitor. KPT-251 induces cancer cell apoptosis and shows antileukemic activity.

HY-14443

XMD8-92	ERK Epigenetic Reader Domain	Cancer
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with K_ds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with K_ds of 190, 600 and 890 nM, respectively. Anti-cancer activity.

HY-147991

PDE5/HDAC-IN-1	Phosphodiesterase (PDE) HDAC Apoptosis	Cancer
PDE5/HDAC-IN-1 (Compound 26) is a potent phosphodiesterase 5 (PDE5) and HDAC inhibitor with IC₅₀ values of 46.3 nM and 14.5 nM, respectively. PDE5/HDAC-IN-1 induces cell apoptosis and shows anticancer activities.

HY-148046

USP15-IN-1
Deubiquitinase Cancer

USP15-IN-1 is a potent USP15 inhibitor with an IC₅₀ value of 3.76 μM. USP15-IN-1 can be used for researching anticancer.

HY-15166A

(E/Z)-Zotiraciclib hydrochloride (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor.

HY-101268

CHMFL-ABL-053	Bcr-Abl Src p38 MAPK	Cancer
CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC₅₀ values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively.

HY-N4287

Nordalbergin
Others Cancer

Nordalbergin, a coumarin isolated from the wood bark of Dalbergia sissoo. Nordalbergin shows strong activity in the induction of differentiation of HL-60.

HY-147202

BRD4 Inhibitor-24	Epigenetic Reader Domain	Cancer
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC₅₀ values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A).

HY-34595

Pyrazoloadenine
RET Cancer

Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity.

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively.

HY-129388B

Pulrodemstat benzenesulfonate CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-16291

APTO-253 LOR-253; LT-253	c-Myc KLF Apoptosis	Cancer Inflammation/Immunology
APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor. APTO-253 has antiarthritic activity.

HY-107426

Verrucarin A Muconomycin A	Apoptosis Reactive Oxygen Species	Cancer
Verrucarin A (Muconomycin A), a Type D macrocyclic mycotoxin derived from the pathogen fungus Myrothecium verrucaria, is an inhibitor of protein synthesis. Verrucarin A inhibits growth of leukemia cell lines and activates caspases and apoptosis and inflammatory signaling in macrophages. Verrucarin A effectively increased the phosphorylation of p38 MAPK and diminished the phosphorylation of ERK/Akt. Verrucarin A caused cell cycle deregulation through the induction of p21 and p53.

HY-100867

TAK-659	Syk FLT3	Cancer
TAK-659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).

HY-116830A

(Rac)-BRD0705	GSK-3	Cancer
(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC₅₀ of 66 nM and a K_d of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC₅₀ of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML).

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective LSD1 inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively.

HY-103274

PD180970	Bcr-Abl Src c-Kit Apoptosis	Cancer Neurological Disease
PD180970 is a highly potent and ATP-competitive p210^Bcr-Abl kinase inhibitor, with an IC₅₀ of 5 nM for inhibiting the autophosphorylation of p210^Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC₅₀s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research.

HY-146724

Dot1L-IN-7	Histone Methyltransferase	Cancer
Dot1L-IN-7 (compound 25) is a potent and selective disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor with an IC50 of 1.0 μM. Dot1L-IN-7 selectively killed Mixed Lineage Leukemia (MLL)-AF9 without showing any effect on the growth of E2A-HLF cells.

HY-100867A

TAK-659 hydrochloride	Syk FLT3	Cancer
TAK-659 hydrochloride is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC₅₀ of 3.2 nM and 4.6 nM for SYK and FLT3, respectively. TAK-659 hydrochloride induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL).

HY-148522

FLT3-IN-18	FLT3	Cancer
FLT3-IN-18 is a potent and selective FLT3 inhibitor with an IC₅₀ value of 0.003 μM. FLT3-IN-18 induces apoptosis and cell cycle arrest at G1 phase. FLT3-IN-18 inhibits FLT3 and STAT5 phosphorylation. FLT3-IN-18 has the potential for the research of acute myeloid leukemia (AML).

HY-106634

Mitoguazone Methylglyoxal-bis(guanylhydrazone); MGBG; Methyl-GAG	HIV Apoptosis	Cancer Infection
Mitoguazone (Methylglyoxal-bis(guanylhydrazone)) is a synthetic polycarbonyl derivative with potent antineoplastic activity. Mitoguazone is a brain-penetrant and competitive S-adenosyl-methionine decarboxylase (SAMDC) inhibitor that disrupts polyamine biosynthesis. Mitoguazone induces cell apoptosis. Mitoguazone inhibits HIV DNA integration into the cellular DNA in both monocytes and macrophages. Mitoguazone has the potential for acute leukemia, Hodgkin's and non-Hodgkin's lymphoma treatment.

HY-120508

Pivanex AN-9; Pivalyloxymethyl butyrate	HDAC Bcr-Abl Apoptosis	Cancer Inflammation/Immunology
Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.

HY-120268A

SLM6031434 hydrochloride	SphK	Cancer Inflammation/Immunology
SLM6031434 hydrochloride is a highly selective sphingosine kinase 2 (SphK2) inhibitor with K_is of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 hydrochloride decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 hydrochloride has the potential for renal fibrosis research.

HY-13653

(-)-Epigallocatechin Gallate EGCG; Epigallocatechol Gallate	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-116830B

BRD5648 (R)-BRD0705	GSK-3	Cancer
BRD5648 ((R)-BRD0705) is a negative control of BRD0705. BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC₅₀ of 66 nM and a K_d of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC₅₀ of 515 nM). BRD0705 can be used for acute myeloid leukemia (AML).

HY-137307

Cholest-5-ene-3ß,22(S)-diol (22S)-Hydroxycholesterol	Others	Inflammation/Immunology
Cholest-5-ene-3ß,22(S)-diol ((22S)-Hydroxycholesterol) is an orally active oxysterol with no significant cytotoxic, oxidative, or inflammatory effects on human prokaryotic leukemia cells. Cholest-5-ene-3ß,22(S)-diol inhibits weight gain and increased serum triacylglycerol (TAG) levels in rat models.

HY-150540

Bcl-2-IN-10	Bcl-2 Family Apoptosis	Cancer
Bcl-2-IN-10 is an active Bcl-2 inhibitor that can release up to four nitric oxide (NO) molecules. Bcl-2-IN-10 has cytotoxic activities against cancer cells, such as human leukemia, breast cancer and lung cancer. Bcl-2-IN-10 induces cell apopotosis and arrest cell cycle of G2/M phase, and can be used in cancer-related research.

HY-N10677

S-30-Hydroxygambogic acid	Others	Cancer
S-30-Hydroxygambogic acid is polyprenylated xanthone epimer that can be isolated from gamboges of Garcinia hanburyi. S-30-Hydroxygambogic acid shows cytotoxicities to Human Leukemia K562 cell lines of IC₅₀ values of 4.49 and 3.61 μM for K562/R and K562/S, respectively. S-30-Hydroxygambogic acid can be used for the research of cancer.

HY-13518

Piceatannol Astringenin; trans-Piceatannol	Syk Autophagy Apoptosis Endogenous Metabolite	Cancer
Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI). Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties. Piceatannol induces apoptosis in DLBCL cell lines. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells.

HY-N10678

R-30-Hydroxygambogic acid	Others	Cancer
R-30-Hydroxygambogic acid is polyprenylated xanthone epimer that can be isolated from gamboges of Garcinia hanburyi. R-30-Hydroxygambogic acid shows cytotoxicities to Human Leukemia K562 cell lines of IC₅₀ values of 2.89 and 1.27 μM for K562/R and K562/S, respectively. R-30-Hydroxygambogic acid can be used for the research of cancer.

HY-151595

Menin-MLL inhibitor-22	Others	Cancer
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC₅₀=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC₅₀=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome).

HY-115446A

Lenalidomide-C4-NH2 hydrochloride Cereblon ligand 1 hydrochloride; E3 ligase Ligand-Linker Conjugates 32 hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C4-NH2 hydrochloride can be connected to the ligand for protein by a linker to form PROTAC (Compound 24), which has IC₅₀s of 0.98 nM and 13.7 nM in inhibition of RS4;11 and MOLM-13 acute leukemia cell lines growth, respectively.

HY-19619

m-3M3FBS	Phospholipase Apoptosis	Cancer
m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis.

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively.

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	RANKL/RANK	Cancer Metabolic Disease Inflammation/Immunology
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells.

HY-16445B

CNDAC hydrochloride	Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis	Cancer
CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis.

HY-15160

TAK-960	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.

HY-147610

CSF1R-IN-9
c-Fms Cancer

CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor with an IC₅₀ of 0.028 μM.
HY-143584

AZ5576
CDK Cancer

AZ5576 is a potent and highly selective CDK9 inhibitor. AZ5576 can be used for hematological Malignancy research.

HY-103159

1-Deazaadenosine	Adenosine Deaminase	Cancer
1-Deazaadenosine is a potent Adenosine deaminase (ADA) inhibitor with a K_i value of 0.66 μM. 1-Deazaadenosine exhibits anti-cancer activities in vitro and has the potential to be a chemotherapy agent for lymphoproliferative disorders.

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.

HY-15160B

TAK-960 dihydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.

HY-147609

CSF1R-IN-8
c-Fms Cancer

CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC₅₀ of 0.012 μM.
HY-147611

CSF1R-IN-10
c-Fms Cancer

CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC₅₀ of 0.005 μM.

HY-139664

GSK-3685032	DNA Methyltransferase	Cancer
GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC₅₀ of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition.

HY-16445A

CNDAC	Nucleoside Antimetabolite/Analog Drug Metabolite Apoptosis DNA/RNA Synthesis	Cancer
CNDAC is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC induces DNA damage and apoptosis.

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.

HY-50907

ABT-737	Bcl-2 Family Apoptosis Autophagy Mitophagy	Cancer
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research.

HY-149912

CZS-241	Polo-like Kinase (PLK) Trk Receptor Apoptosis	Cancer
CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC₅₀=2.6 nM). CZS-241 inhibits TRKA with an IC₅₀ value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines.

HY-111640

3'-Azido-3'-deoxy-5-methylcytidine	HIV Reverse Transcriptase	Infection
3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (XMRV) inhibitor with a CC₅₀ of 43.5 μM in MCF-7 cells. 3'-Azido-3'-deoxy-5-methylcytidine also inhibits HIV-1 reverse transcriptase with an EC₅₀ of 0.06 μM in peripheral blood mononuclear (PBM) cells.

HY-150526

EGCG-4″-sulfate	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology
EGCG-4″-sulfate is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate sulfate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. EGCG-4″-sulfate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-132307

Mcl-1 inhibitor 6	Bcl-2 Family Apoptosis	Cancer
Mcl-1 inhibitor 6 is an orally active, selective *myeloid cell leukemia* 1 (Mcl-1) protein inhibitor with a K_d of 0.23 nM and a K_i** of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, K_d>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent.

HY-131061

BET bromodomain inhibitor 1	Epigenetic Reader Domain	Cancer
BET bromodomain inhibitor 1 is an orally active, selective bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC₅₀ of 2.6 nM for BRD4. BET bromodomain inhibitor 1 binds to BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with high affinities (K_d values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, 2.1 nM, respectively). bromodomain inhibitor 1 has anti-cancer activity.

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.

HY-143317

XY153	Epigenetic Reader Domain	Cancer
XY153 (compound 8l) is a BD2-selective BET inhibitor and selectively binds to BRD4 BD2. XY153 binds to BRD4 BD2, BRD3 BD2 and BRD2 BD2 with IC₅₀s of 0.79, 5.31 and 5.09 nM, respectively. XY153 shows potent antiproliferative activity against multiple tumor cell lines. XY153 can be used for the research of acute myeloid leukemia (AML) and cancer.

HY-10943

GNF-7	Bcr-Abl Ack1	Cancer
GNF-7 is a multikinase inhibitor. GNF-7 is a Bcr-Abl inhibitor, with IC₅₀s of 133 nM and 61 nM for Bcr-Abl^WT and Bcr-Abl^T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC₅₀s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies.

HY-141796

MS67	Histone Methyltransferase PROTACs	Cancer
MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a K_d of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects.

HY-13735A

Quinacrine dihydrochloride Mepacrine dihydrochloride; SN-390 dihydrochloride	Parasite Apoptosis Autophagy Mitophagy	Cancer Infection
Quinacrine (Mepacrine) dihydrochloride is an orally bioavailable antimalarial agent, which possess anticancer effect both in vitro and vivo. Quinacrine dihydrochloride suppresses NF-κB and activate p53 signaling, which results in the induction of the apoptosis.

HY-115979

Sirt2-IN-5
Sirtuin Cancer Neurological Disease

Sirt2-IN-5 is a potent SIRT2 inhibtor.

HY-132233A

DDO-2093 dihydrochloride	Histone Methyltransferase	Cancer
DDO-2093 dihydrochloride is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC₅₀=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 dihydrochloride selectively inhibits the catalytic activity of MLL complex.

HY-129390

Orelabrutinib ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

HY-13001

Quizartinib AC220	FLT3 Ligands for Target Protein for PROTAC Apoptosis Autophagy	Cancer
Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC₅₀s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Cancer Inflammation/Immunology
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.

HY-13735B

Quinacrine hydrochloride hydrate Mepacrine hydrochloride hydrate; SN-390 hydrochloride hydrate	Parasite Apoptosis Autophagy Mitophagy	Cancer Infection
Quinacrine hydrochloride hydrate (Mepacrine hydrochloride hydrate) is an antimalarial agent, which possess anticancer effect both in vitro and vivo. Quinacrine hydrochloride hydrate suppresses NF-κB and activates p53 signaling, which results in the induction of the apoptosis.

HY-144693

MEK/PI3K-IN-2	MEK PI3K PERK	Cancer
MEK/PI3K-IN-2 (compound 6s) is a potent MEK/PI3K inhibitor, with IC₅₀ values of 352 nM (MEK1), 107 nM (PI3Kα), and 137 nM (PI3Kδ), respectively. MEK/PI3K-IN-2 suppresses pAKT and pERK1/2 levels. MEK/PI3K-IN-2 shows anti-proliferative activity against tumor cell lines.

HY-136268

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth.

HY-144692

MEK/PI3K-IN-1	MEK PI3K PERK	Cancer
MEK/PI3K-IN-1 (compound 6r) is a potent MEK/PI3K inhibitor, with IC₅₀ values of 124 nM (MEK1), 130 nM (PI3Kα), and 236 nM (PI3Kδ), respectively. MEK/PI3K-IN-1 suppresses pAKT and pERK1/2 levels. MEK/PI3K-IN-1 shows anti-proliferative activity against tumor cell lines.

HY-132233

DDO-2093	Histone Methyltransferase	Cancer
DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC₅₀=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.

HY-15187B

Filanesib TFA ARRY-520 TFA	Kinesin	Cancer
Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC₅₀ of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity.

HY-N8493

Mycalolide B	Others	Others
Mycalolide-B is a specific inhibitor of actomyosin ATPase isolated from marine sponge. Mycalolide-B inhibits ATP-induced contraction and Mg²⁺-ATPase activity in the absence of Ca²⁺.

HY-119769

XX-650-23	Epigenetic Reader Domain	Cancer
XX-650-23 is a potent CREB inhibitor. XX-650-23inhibits CREB function through disruption of CBP-CREB interaction. XX-650-23 can be used for AML research.

HY-15187

Filanesib ARRY-520	Kinesin Apoptosis	Cancer
Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC₅₀ of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.

HY-114414

HDACs/mTOR Inhibitor 1	HDAC mTOR Apoptosis	Cancer
HDACs/mTOR Inhibitor 1 is a dual HDACs and mTOR inhibitor, with IC₅₀s of 0.19 nM, 1.8 nM, 1.2 nM for HDAC1, HDAC6, mTOR, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induces tumor cell apoptosis with low toxicity in vivo. HDACs/mTOR Inhibitor 1 can be used in the research of hematologic malignancies.

HY-12372

Sanggenon G	IAP Caspase	Cancer
Sanggenon G is a cell-permeable and potent inhibitor of X-linked inhibitor of apoptosis protein (XIAP). Sanggenon G binds specifically to the BIR3 domain of XIAP with a binding affinity of 34.26 μM. Sanggenon G enhances caspase activation.

HY-N7175

5,8-Epidioxyergosta-6,9(11),22-trien-3-ol 9,11-Dehydroergosterol peroxide; 9(11)-DHEP	Apoptosis Endogenous Metabolite	Cancer
5,8-Epidioxyergosta-6,9(11),22-trien-3-ol (9,11-Dehydroergosterol peroxide), an important steroid from medicinal mushroom, exerts antitumor activity in several tumor types. 5,8-Epidioxyergosta-6,9(11),22-trien-3-ol inhibits HT29 cell growth by inducing CDKN1A expression, thus causing cell cycle arrest and apoptosis.

HY-138617

AI-10-47
Others Cancer

AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC₅₀ of 3.2 μM.

HY-146277A

CBP/p300-IN-19 hydrochloride	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity.

HY-130854

Thalidomide-NH-C6-NH-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis. MI-389 is a potent phthalimide PROTAC degrader based on the multi-targeted receptor tyrosine kinase inhibitor sunitinib (HY-10255A).

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells.

HY-153112

DHODH-IN-23
Dihydroorotate Dehydrogenase Cancer

DHODH-IN-23 (Compound A) is an orally active DHODH inhibitor that can be used for the research of cancer.

HY-13629

Etoposide VP-16; VP-16-213	Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Cancer Infection
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.

HY-12583

A-366	Histone Methyltransferase Epigenetic Reader Domain	Cancer
A-366 is a potent, highly selective, peptide-competitive histone methyltransferase G9a inhibitor with IC₅₀s of 3.3 and 38 nM for G9a and GLP (EHMT1), respectively. A-366 shows >1000-fold selectivity over 21 other methyltransferases. A-366 is also a potent, nanomolar inhibitor of the Spindlin1-H3K4me3-interaction (IC₅₀=182.6 nM). A-366 displays high affinity at human histamine H3 receptor (K_i=17 nM) and shows subtype selectivity among subsets of the histaminergic and dopaminergic receptor families.

HY-136499

DI-82
Others Cancer

DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC₅₀^app of 27.8 nM and K_i^app of 9.2 nM. DI-82 has antitumor activity.

HY-146277

CBP/p300-IN-19	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity.

HY-19825

Rebeccamycin	Topoisomerase ADC Cytotoxin Antibiotic	Cancer
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.

HY-15815

Bromosporine	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Metabolic Disease Cardiovascular Disease
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-143895

FLT3-IN-12	FLT3	Cancer
FLT3-IN-12 is a potent, selective and orally active FLT3 kinase inhibitor with IC₅₀s of 1.48 nM and 2.87 nM for FLT3-WT and FLT3-D835Y, respectively. FLT3-IN-12 possesses high selectivity over c-KIT (>1000-fold). FLT3-IN-12 has an excellent anti-AML (acute myeloid leukemia) activity (MV4-11, IC₅₀ of 0.75 nM).

HY-124500

AC-4-130	STAT Apoptosis	Cancer
AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML).

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-134557

GS87	GSK-3	Cancer
GS87 is a highly specific and potent GSK3 inhibitor with IC₅₀s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research.

HY-108359

Alsterpaullone 9-Nitropaullone; NSC 705701	CDK GSK-3 Apoptosis	Cancer
Alsterpaullone (9-Nitropaullone) is a potent CDK inhibitor, with IC₅₀s of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also competes with ATP for binding to GSK-3alpha/GSK-3beta with IC₅₀s of both 4 nM. Alsterpaullone has antitumor activity, and possesses potential for the study in neurodegenerative and proliferative disorders. Alsterpaullone induces apoptosis in leukemia cell line.

HY-13599

Cladribine 2-Chloro-2′-deoxyadenosine; CldAdo; 2CdA	Adenosine Deaminase Apoptosis	Cardiovascular Disease Cancer
Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis.

HY-12707

Piribedil	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Cancer Endocrinology Neurological Disease
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers.

HY-12707A

Piribedil dihydrochloride	Adrenergic Receptor Dopamine Receptor Histone Methyltransferase	Cancer Endocrinology Neurological Disease
Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers.

HY-17547

NMS-E973	HSP	Cancer
NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC₅₀ of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy.

HY-12707C

Piribedil hydrochloride	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Cancer Endocrinology Neurological Disease
Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers.

HY-129602

SD-36	PROTACs STAT Apoptosis	Cancer
SD-36 is a potent and efficacious STAT3 PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC₅₀=10 nM). SD-36 exerts robust anti-tumor activity, and achieves complete and long-lasting tumor regression in mouse tumor models. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase.

HY-N10264

Avrainvillamide (+)-Avrainvillamide; CJ-17,665	Antibiotic	Cancer Infection
Avrainvillamide ((+)-Avrainvillamide) is a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Avrainvillamide affects cell biology both by directly binding NPM1 and Crm1 as well as by inhibiting the association of these proteins with certain native cellular partners. Avrainvillamide, an antibiotic, inhibits growth of multi-agent resistant Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, with MICs of 12.5, 12.5 and 25 μg/ml, respectively.

HY-122919

Momordicoside L
Others Cancer

Momordicoside L is a Cucurbitane Triterpenoid, that can be isolated from the leaves of Momordica charantia. Momordicoside L shows anticancer activity.

HY-144766

ATX inhibitor 13	Apoptosis	Cancer
ATX inhibitor 13 (10c) is an orally active and potent ATX inhibitor, with an IC₅₀ of 3.4 nM. ATX inhibitor 13 inhibits proliferation and migration, and induces apoptosis and G2 phase arrest in RAW264.7 cells. ATX inhibitor 13 suppresses tumor cell colony formation.

HY-135231

NL-1	Mitochondrial Metabolism Autophagy	Cancer
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC₅₀s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.

HY-130612

PROTAC BRD2/BRD4 degrader-1	Epigenetic Reader Domain PROTACs	Cancer
PROTAC BRD2/BRD4 degrader-1 (compound 15) is a potent and selective BET protein BRD4 and BRD2 degrader, connected by ligands for Cereblon and BET. PROTAC BRD2/BRD4 degrader-1 rapidly induces reversible, long-lasting, and unexpectedly selective removal of BRD4 and BRD2 over BRD3. It effectively inhibits solid tumors with low cytotoxic effect. PROTAC BRD2/BRD4 degrader-1 is composed of the BET inhibitor, a linker, and the ligand thalidomide for cereblon (CRBN)/cullin 4A.

HY-148683

EG-011	Arp2/3 Complex	Cancer
EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas.

HY-137471

RBPJ Inhibitor-1 RIN1	Notch	Cancer
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.

HY-13630A

Etoposide phosphate disodium BMY-40481 disodium	Topoisomerase Autophagy Apoptosis	Cancer Neurological Disease
Etoposide phosphate disodium (BMY-40481 disodium) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor?to prevent re-ligation of DNA strands. Etoposide phosphate disodium is the phosphate ester proagent of etoposide and is considered as?active?equivalent to Etoposide. Etoposide phosphate disodium induces cell cycle arrest,?apoptosis, and?autophagy.

HY-116852

Thiocolchicine	Microtubule/Tubulin Apoptosis	Cancer
Thiocolchicine, a derivative modified in the C Ring of Colchicine (HY-16569) with enhanced biological properties. Thiocolchicine is a potent inhibitor of tubulin polymerization (IC₅₀=2.5 µM) and competitively binds to tubulin with a K_i of 0.7 µM. Thiocolchicine induces cell apoptosis. Thiocolchicine can be used as an ADC cytotoxin in ADC technology.

HY-13630

Etoposide phosphate BMY-40481	Topoisomerase Bacterial Autophagy Apoptosis	Cancer Infection Neurological Disease
Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor?to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as?active?equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest,?apoptosis, and?autophagy.

HY-101991

ML291	PERK Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
ML291 is a UPR (unfolded protein response)-inducing sulfonamidebenzamide. ML291 overwhelms the adaptive capacity of the UPR and induces apoptosis in a variety of solid cancer models. ML291 can activate the PERK/eIF2a/CHOP (apoptotic) arm of the UPR and reduce leukemic cell burden.

HY-108466

Ro 08-2750	Apoptosis	Cancer Neurological Disease
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC₅₀ of ~ 1 µM. Ro 08-2750 inhibits NGF binding to p75^NTR selectively over TRKA. Ro 08-2750 is a selective _{MSI RNA-binding} activity inhibitor, with an IC₅₀ of 2.7 μM.

HY-144777

FLT3-IN-14	FLT3 Apoptosis	Cancer
FLT3-IN-14 is a potent FLT3 inhibitor with IC₅₀s of 5.6 nM and 1.4 nM for FLT3-WT and FLT3-ITD. FLT3-IN-14 reduces the phosphorylation of FLT3 (Y591), induces cell cycle arrest at G1 phase and apoptosis. FLT3-IN-14 significantly reduces the tumor growth in an MV4-11 xenograft mouse model.

HY-16050

Plitidepsin Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Cancer Infection
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.

HY-151411

RUNX1/ETO tetramerization-IN-1	Others	Cancer
RUNX1/ETO tetramerization-IN-1 is a small-molecule inhibitor of RUNX1/ETO tetramerization, exhibits anti-leukemic effect. RUNX1/ETO tetramerization-IN-1 specifically targets to NHR2 of RUNX1/ETO (EC₅₀=0.25 μM), restores gene expression down-regulated by RUNX1/ETO. RUNX1/ETO tetramerization-IN-1 inhibits the proliferation of RUNX1/ETO-depending SKNO-1 cells, and reduces the RUNX1/ETO-related tumor growth in a mouse model.

HY-144433

DNMT3A-IN-1	DNA Methyltransferase	Infection
DNMT3A-IN-1 is a potent and selective DNMT3A inhibitor. DNMT3A-IN-1 shows inhibitor activities against DNMT3A with k_I values range from 9.16-18.85 μM (AdoMet) and 11.37-23.34 μM (poly dI-dC) .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies.

HY-117718

AG957 Tyrphostin AG957; NSC 654705	Bcr-Abl	Cancer
AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity. AG957 is a bcr/abl kinase inhibitor with an IC₅₀ of 2.9 μM for p210^bcr/abl autokinase activity.

HY-122903

TK216	DNA/RNA Synthesis	Cancer
TK216 is an orally active and potent E26 transformation specific (ETS) inhibitor. TK216 directly binds EWS-FLI1 and inhibits EWS-FLI1 protein interactions. TK216 blocks the binding between EWS-FLI1 and RNA helicase A. TK216 has anticancer activity.

HY-139514

RB-3
E1/E2/E3 Enzyme Cancer

RB-3, a PRC1 inhibitor, binds to RING1B-BMI1f, with a K_d of 2.8 μM.

HY-146021

Topoisomerase IIα-IN-2	Topoisomerase	Cancer
Topoisomerase IIα-IN-2 (compound 5) is a potent DNA-binding ligands and topoisomerase IIα inhibitor. Topoisomerase IIα-IN-2 exhibits high antiproliferative activity against human cancer cell lines. Topoisomerase IIα-IN-2 significantly induces DNA damage and arrests cancer cells at G2/M phase.

HY-146020

Topoisomerase IIα-IN-1	Topoisomerase	Cancer
Topoisomerase IIα-IN-1 (compound 2) is a potent DNA-binding ligands and topoisomerase IIα inhibitor. Topoisomerase IIα-IN-1 exhibits high antiproliferative activity against human cancer cell lines.

HY-16700

PNU-159682	ADC Cytotoxin Topoisomerase	Cancer
PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated?ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.

HY-N2306

Aclacinomycin A Aclarubicin	Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic	Cancer
Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.

HY-151407

CDK1-IN-3	CDK	Cancer
CDK1-IN-3 (8g) is a selective CDK1 inhibitor with IC₅₀s of 36.8, 305.17 and 369.37 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-3 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-3 can be used for the research of cancer.

HY-14521

Lometrexol DDATHF	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor.

HY-14521A

Lometrexol disodium DDATHF disodium	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) disodium, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol disodium can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol disodium has anticancer activity. Lometrexol disodium also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor.

HY-151408

CDK1-IN-4	CDK	Cancer
CDK1-IN-4 (10d) is a selective CDK1 inhibitor with IC₅₀s of 44.52, 624.93 and 135.22 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN4 inhibits the growth of cancer cells by affecting cell cycle. CDK1-IN-4 can be used for the research of cancer.

HY-151409

CDK1-IN-5	CDK	Cancer
CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC₅₀s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer.

HY-10475G

AM580 CD336; NSC608001; Ro 40-6055	RAR/RXR	Cancer
AM580 (CD336) (GMP) is AM580 (HY-10475) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AM580 is a selective RARα agonist.

HY-14521B

Lometrexol hydrate DDATHF hydrate	Antifolate Apoptosis Caspase Bcl-2 Family	Cancer
Lometrexol (DDATHF) hydrate, an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol hydrate can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol hydrate has anticancer activity. Lometrexol hydrate also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor.

HY-144673

LSD1-IN-12	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-12 (compound 2) is a potent LSD1 inhibitor, with K_i values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively.

HY-N3451

Isothymusin	Lipoxygenase	Cancer
Isothymusin is a potent anti-oxidant agent. Isothymusin shows radical scavenging activities. Isothymusin shows anti-proliferative activities in cancer cell lines. Isothymusin inhibited the enzymes associated with the promotion stage of cancer, including cycloxygenase- 2 and lipoxygenase-5.

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.

HY-136650

Fludarabine triphosphate F-ara-ATP	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP), the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis.

HY-141890

BAZ1A-IN-1	Epigenetic Reader Domain	Cancer
BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a K_D value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A.

HY-151190

cis-4-Br-2,5-F2-PCPA S1024	Histone Demethylase	Cancer
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 94 nM instead of 8.4 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits LSD1 cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells.

HY-136650A

Fludarabine triphosphate trisodium F-ara-ATP trisodium	Nucleoside Antimetabolite/Analog Drug Metabolite DNA/RNA Synthesis Apoptosis	Cancer
Fludarabine triphosphate (F-ara-ATP) trisodium, the active metabolite of Fludarabine (HY-B0069), is a potent, noncompetitive and specific inhibitor of DNA primase, with an IC₅₀ of 2.3 μM and a K_i of 6.1 μM. Fludarabine triphosphate trisodium inhibits DNA synthesis by blocking DNA primase and primer RNA formation. Fludarabine triphosphate trisodium inhibits ribonucleotide reductase and DNA polymerase and ultimately leads to cellular apoptosis.

HY-14951

Firategrast SB 683699	Integrin	Neurological Disease
Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity.

HY-114358

Tamnorzatinib ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC₅₀ values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of?EGFR-mutated non-small cell lung cancer (NSCLC).

HY-151192

LSD1/2-IN-3	Histone Demethylase	Cancer
LSD1/2-IN-3 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 11 nM instead of 7 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, LSD1/2-IN-1 inhibits LSD1 cell proliferation.

HY-147901

KDM1/CDK1-IN-1	Histone Demethylase CDK Apoptosis Caspase	Cancer
KDM1/CDK1-IN-1 (compound 4) is a potent KDM1 and CDK1 inhibitor, with IC₅₀ values of 0.096 and 0.078 μM, respectively.KDM1/CDK1-IN-1 induces cell cycle arrest at G2/M phase and apoptosis in HOP-92 cells. KDM1/CDK1-IN-1 exhibits potent cytotoxic activity against the CCRF-CEM, HOP-92 and Hep-G2 cells, with IC₅₀ values of 16.34, 3.45 and 7.79 μM, respectively.

HY-120758

SEL24-B489	Pim FLT3 Apoptosis	Cancer
SEL24-B489 is a potent, type I, orally active, dual PIM and FLT3-ITD inhibitor, with K_d values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.

HY-17600S

Acalabrutinib-d4 ACP-196-d₄	Btk	Cancer
Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1].

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Cancer Inflammation/Immunology
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity.

HY-133136

PROTAC BRD4 Degrader-2
PROTACs Epigenetic Reader Domain Cancer

PROTAC BRD4 Degrader-2 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 14.2 nM against BRD4 BD1.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis Endogenous Metabolite	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Cancer Inflammation/Immunology Cardiovascular Disease
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

Cat. No.	Product Name

HY-L003

Apoptosis Compound Library

1905 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 1905 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

HY-L079

Anti-Blood Cancer Compound Library

2311 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 2311 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L135

Cancer Stem Cells Compound Library

1830 compounds

With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.

Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.

MCE supplies a unique collection of 1830 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Cat. No.	Product Name	Type

HY-D0153

Tetramethylrhodamine-5-isothiocyanate	Fluorescent Dyes/Probes
Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles.

HY-N2306

Aclacinomycin A Aclarubicin	Fluorescent Dyes/Probes
Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.

Cat. No.	Product Name	Type

HY-E70016

Terminal deoxyribonucleotidyltransferase TdT	Enzyme
Terminal deoxyribonucleotidyltransferase (TdT) catalyses the condensation of deoxyribonucleotide triphosphates onto the 3' hydroxyl ends of DNA strands and adds N-regions to gene segment junctions during V(D)J recombination. Terminal deoxyribonucleotidyltransferase is expressed in immature, pre-B, pre-T lymphoid cells, and acute lymphoblastic leukemia/lymphoma cells.

Cat. No.	Product Name	Target	Research Area

HY-129283A

Goralatide TFA	Peptides	Cancer
Goralatide TFA is an inhibitor of cell cycle progression. Goralatide TFA enhances selectivity of hyperthermic purging of human progenitor cells. Goralatide TFA has the potential for the research of leukemia.

HY-P1613

Cyclo(Arg-Gly-Asp-D-Phe-Val)	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia.

HY-P1613A

Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA	Integrin Apoptosis	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia.

HY-129407A

AAF-CMK	Ser/Thr Protease Apoptosis	Cancer
AAF-CMK is a TPPII (tripeptidylpeptidase II) inhibitor, shows anti-tumor activity and induces apoptosis. AAF-CMK can be used in leukemia research.

HY-19554

MM-401	Histone Methyltransferase Apoptosis	Cancer
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC₅₀ = 0.32 µM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.

HY-P3508

PNC-27
Peptides Cancer

PNC-27 is an anticancer peptide, containing an HDM-2-binding domain. PNC-27 shows anti-tumor activity and can be used in acute myeloid leukemia research.

HY-P1923

L-Asparaginase L-ASNase	Apoptosis DNA/RNA Synthesis	Cancer
L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis.

HY-P2267

LDV
Integrin Others

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells.

HY-P1785

Abl Cytosolic Substrate	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus.

HY-P3736

Myelopeptide-2 MP-2	Interleukin Related	Cancer
Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.

HY-105172

TT-232 CAP-232; TLN-232	Somatostatin Receptor	Cancer Inflammation/Immunology
TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent.

HY-16050

Plitidepsin Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Cancer Infection
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.

HY-137874

L-Glutamic γ-monohydroxamate	Peptides	Cancer Metabolic Disease
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo.

Cat. No.	Product Name	Target	Research Area

HY-P9963

Blinatumomab Anatumomab	Inhibitory Antibodies	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia.

HY-P99207

Lenzilumab KB 003	SARS-CoV	Cancer
Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies.

HY-P99034

Moxetumomab
ADC Antibody CD22 Cancer Inflammation/Immunology

Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL).

HY-P99285

Denintuzumab hBU 12	ADC Antibody CD19	Others
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia.

HY-P99233

Camidanlumab HuMax-TAC	Interleukin Related	Cancer
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia.

HY-P99014

Cusatuzumab	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML).

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Inhibitory Antibodies	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).

HY-P99442

Apolizumab Hu1D10	Apoptosis	Inflammation/Immunology
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro.

HY-P99971

Gemtuzumab	Antibody-Drug Conjugates (ADCs)	Cancer
Gemtuzumab (Gemtuzumab ozogamicin) is an antibody-drug conjugate targeting to CD33 on tumor cells. Gemtuzumab consists of a cytotoxic derivative of calicheamicin and a humanised monoclonal IgG4 antibody. CD33 is specifically expresses on the surface of leukaemic cell blasts in acute myeloid leukemia (AML) patients. Gemtuzumab can be used for research of AML.

HY-P99258

Brontictuzumab OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody	Notch	Cancer
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.

HY-P99208

Lirilumab IPH2102	Inhibitory Antibodies	Cancer
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.

HY-P99400

Samalizumab ALXN 6000	Inhibitory Antibodies	Cancer
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research.

HY-P99412

Lusvertikimab OSE-127	Interleukin Related	Cancer
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research.

HY-P99255

Moxetumomab pasudotox CAT 8015; HA 22; Anti-Human CD22 Recombinant Antibody	Antibody-Drug Conjugates (ADCs) CD22	Cancer
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F_v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL).

HY-P99264

Inotuzumab Humanized Anti-CD22 Recombinant Antibody	ADC Antibody CD22	Cancer
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.

HY-P99253

Mogamulizumab KW-0761	CCR	Cancer Inflammation/Immunology
Mogamulizumab (KW-0761) is a defucosylated humanized recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL).

HY-P99651

Grisnilimab setaritox WT1-RTA	Inhibitory Antibodies	Cancer
Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID₅₀ of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys.

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).

HY-P99261

Demcizumab OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody	Notch	Cancer
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models.

HY-P99173

MDX-1342	Inhibitory Antibodies	Cancer
MDX-1342 is a fully human monoclonal antibody (HuMAb) of targeting CD19-membrane receptor. MDX-1342 can specifically bind to human CD19 antigen with high affinity and has antibody-dependent cellular cytotoxicity (ADCC) effect. MDX-1342 can be used for the research of B-lymphocyte malignancies and autoimmune.

Cat. No.	Product Name	Target	Category

HY-119784

Eupenifeldin	Others	Phenols Monophenols Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Eupenifeldin is pentacyclic bistropolone isolated from cultures of Eupenicillium brefeldianum ATCC 74184. Eupenifeldin is cytotoxic against the HCT-116 cell line. Eupenifeldin has the potential for the research of leukemia.

HY-126030

(+)-Syringaresinol	Nuclear Factor of activated T Cells (NFAT)	Phenylpropanoids Phenols Polyphenols Structural Classification Lignans Compositae Antheroporum pierrei Gagnep. Plants Source classification Disease Research Fields Cancer Classification of Application Fields
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC₅₀ of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia.

HY-N10206

11-epi-Chaetomugilin I	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
11-epi-Chaetomugilin I is a metabolite found in Chaetomium globosum. 11-epi-Chaetomugilin I exhibits significant cytotoxic activity against the murine P388 leukemia cell line, the human HL-60 leukemia cell line, the murine L1210 leukemia cell line, and the human KB epidermoid carcinoma cell line.

HY-N0128

Sclareol	Apoptosis	Terpenoids Diterpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Labiatae Erigeron breviscapus (Vant.) Hand.-Mazz. Salvia sclarea
Sclareol is isolated from Salvia sclarea with anticarcinogenic activity. Sclareol shows strong cytotoxic activity against mouse leukemia (P-388), human epidermal carcinoma (KB) cells and human leukemia cell lines. Sclareol induces cell apoptosis.

HY-N8386

Berkeleylactone F	Antibiotic	Ketones, Aldehydes, Acids Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
Berkeleylactone F is an antibiotic macrolide compound. Berkeleylactone F showed modest inhibition of CCRF-CEM leukemia cells.

HY-N7651

Neoanhydropodophyllol	Others	Phenylpropanoids Lignans Classification of Application Fields Disease Research Fields Cancer Source classification Plants Berberidaceae Dysosma versipellis (Hance) M. Cheng ex Ying
Neoanhydropodophyllol is a cyclolignan derivative, with antineoplastic activity. Neoanhydropodophyllol displays cytotoxicity against several cancer cells (leukemia, lung carcinoma and colon carcinoma).

HY-N2387

Pinosylvin	Bacterial Apoptosis Autophagy	Phenols Stilbenes Polyphenols Infection Disease Research Fields Classification of Application Fields Source classification Plants Polygonaceae Reynoutria japonica Houtt.
Pinosylvin is a pre-infectious stilbenoid toxin isolated from the heartwood of Pinus species, has anti-bacterial activities. Pinosylvin is a resveratrol analogue, can induce cell apoptosis and autophapy in leukemia cells.

HY-N0564

Notopterol	Apoptosis	Phenylpropanoids Coumarins Classification of Application Fields Disease Research Fields Inflammation/Immunology Neurological Disease Source classification Plants Umbelliferae Notopterygium incisum Ting ex H. T. Chang
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML).

HY-102010

Pancratistatin (+)-Pancratistatin	Apoptosis	Structural Classification Natural Products Hymenocallis littoralis (Jacq.) Salisb. Amaryllidaceae Plants Source classification
Pancratistatin is an isoquinoline alkaloid that can be isolated from Hymenocallis littoralis. Pancratistatin induces apoptosis of human melanoma cells. Pancratistatin can be used for the research of neuroblastoma, leukemia and breast cancer.

HY-N10364

6β,7β-Epoxyasteriscunolide A	Others	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
6β,7β-Epoxyasteriscunolide A, a sesquiterpenoid, shows cytotoxicity against the HL-60 and MOLT-3 leukemia cell lines, with IC₅₀s range 4.1-5.4 μM.

HY-N1830

3-Epiwilsonine	Others	Alkaloids Other Alkaloids Source classification Plants Taxaceae Cephalotaxus sinensis var. wilsoniana (Hayata) L. K. Fu & Nan Li
3-Epiwilsonine is an alkaloid from Cephalotaxus wilsoniana, exhibits effect on acute and chronic myeloid leukemia and malignant lymphoma.

HY-N9210

1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid	Others	Ketones, Aldehydes, Acids Source classification Plants Euphorbiaceae
1,2,3-Tri-O-methyl-7,8-methyleneflavellagic acid, a ellagic acid derivative of Agrostistachys hookeri, exhibits activity against cultured P-388 lymphocytic leukemia cells.

HY-121412

Lankacidin C	Antibiotic Bacterial	Structural Classification Antibiotics Microorganisms Source classification
Lankacidin C is an inhibitor of protein synthesis in vitro. Lankacidin C inhibits the activity of L1210 leukemia, B16 melanoma and 6C3 HED/OG lymphosarcoma cell lines. Lankacidin C has antibacterial activity and antitumor activity.

HY-N1649

2,3,2'',3''-Tetrahydroochnaflavone	Others	Flavonoids Biflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Source classification Plants Paracryphiaceae Boesenbergia pandurate
2,3,2'',3''-Tetrahydroochnaflavone is a biflavonoid, which can be isolated from the leaves of Quintinia acutifolia. 2,3,2'',3''-Tetrahydroochnaflavone shows some cytotoxicity against P388 murine lymphocytic leukemia cells, with an IC₅₀ of 8.2 µg/mL.

HY-N7634

Tectol	Farnesyl Transferase Parasite	Phenols Polyphenols Structural Classification other families Plants Source classification Infection Disease Research Fields Classification of Application Fields
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM. Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM.

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Apoptosis	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity.

HY-112328

Fascaplysin	Apoptosis Autophagy Reactive Oxygen Species	Indole Alkaloids Alkaloids Structural Classification Sponge Marine natural products Animals Infection Disease Research Fields Cancer Classification of Application Fields
Fascaplysin is an antimicrobial and cytotoxic red pigment, that can come from the marine sponge (Fascaplysinopsis sp.). Fascaplysin has been synthesized in seven steps from indole (65% yield). Fascaplysin can induces apoptosis and autophagy in human leukemia HL-60 cells. Fascaplysin shows anti-tumor activity.

HY-N0117

Indirubin Couroupitine B; Indigo red; Indigopurpurin	Apoptosis	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants other families
Indirubin (Couroupitine B) is a bis-indole alkaloid and has emarkable anticancer activity against chronic myelocytic leukemia.

HY-N0990

1,5,15-Trimethylmorindol	Others	Anthraquinones Source classification Plants Rubiaceae Morinda citrifolia Linn.
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay.

HY-13062A

Daunorubicin Daunomycin; RP 13057; Rubidomycin	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Autophagy Bacterial Antibiotic Apoptosis	Quinones Anthraquinones Phenols Polyphenols Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

HY-13062

Daunorubicin hydrochloride Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride	Topoisomerase DNA/RNA Synthesis ADC Cytotoxin Bacterial Autophagy Apoptosis Antibiotic	Quinones Anthraquinones Phenols Polyphenols Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor.

HY-N10591

Bruceantarin	Others	Structural Classification Natural Products Simaroubaceae Brucea javanica (L.) Merr. Plants
Bruceantarin is a potent antineoplastic agent. Bruceantarin can be used for leukemia and breast cancer research.

HY-N2517

Dihydroevocarpine	mTOR	Alkaloids Quinoline Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Rutaceae Evodia rutaecarpa (Juss.) Benth.
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity.

HY-N6733

Aphidicolin	DNA/RNA Synthesis HSV Apoptosis Antibiotic Orthopoxvirus	Terpenoids Diterpenoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Microorganisms
Aphidicolin is an inhibitor of DNA polymerase α and δ, prevents mitotic cell division by interfering DNA polymerase activity. Aphidicolin is an antibiotic produced by mold Cephalosporium aphidicola, inhibits cellular deoxyribonucleic acid synthesis and the growth of herpes simplex virus. Aphidicolin exhibits anti-orthopoxvirus activity and potentiates apoptosis induced by arabinosyl nucleosides in a human promyelocytic leukemia cell line.

HY-19356

Rocaglamide Roc-A	NF-κB HSP Eukaryotic Initiation Factor (eIF)	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Meliaceae Aglaia elliptifolia
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.

HY-N5007

Galgravin	Apoptosis	Phenylpropanoids Lignans Classification of Application Fields Disease Research Fields Cancer Source classification Plants Magnoliaceae Magnolia Liliflora Desr.
Galgravin is an active compound in Nectandra megapotamica, with anti-inflammatory activity. Galgravin displays in vitro cytotoxic activity and induce apoptosis in leukemia cells.

HY-N6037

Gardenin B	Apoptosis	Monophenols Phenols Flavones Flavonoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Rubiaceae Gardenia jasminoides Ellis
Gardenin B is a flavonoid isolated from Gardenia jasminoides. Gardenin B induces cell death in human leukemia cells involves multiple caspases.

HY-N3308

Medicarpin	Apoptosis	Monophenols Phenols Structural Classification Leguminosae Medicago sativa L. Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Medicarpin is a flavonoid isolated from Medicago sativa. Medicarpin induces apoptosis and overcome multidrug resistance in leukemia P388 cells by modulating P-gp-mediated efflux of agents.

HY-N2732

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Others	Structural Classification Flavones Flavonoids Plants Source classification Maclura pomifera (Raf.) Schneid. Moraceae
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells.

HY-N6017

Bakkenolide A	HDAC	Terpenoids Sesquiterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Compositae Corethrodendron multijugum (Maximowicz) B. H. Choi & H. Ohashi
Bakkenolide A is a natural product extracted from Petasites tricholobus. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.

HY-N8390

3-Epidehydropachymic acid	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Polyporaceae Poria cocos
3-Epidehydropachymic acid, a lanostane triterpenoid, shows totoxicity effect against human acute monocytic leukemia cell line THP-1 (IC₅₀=52.51 μM).

HY-N0840

Bruceantin (-)-Bruceantin; NCI165563; NSC165563	Others	Terpenoids Diterpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Simaroubaceae Brucea javanica (L.) Merr. Brucea antidysenterica J.F.Mill.
Bruceantin(NSC165563) is first isolated from Brucea javanica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, colon 38, and L1210 and P388 leukemia in mice.

HY-N2108

7-Ethylcamptothecin	Others	Alkaloids Quinoline Alkaloids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Nyssaceae Camptotheca acuminata Decne. other families
7-Ethylcamptothecin is one of camptothecin analogues. camptothecin (CPT), a cytotoxic alkaloid isolated from Camptotheca acuminata, is shown to have strong antitumor activity against L1210 leukemia and Walker 256 carcinosarcoma models.

HY-N0488A

Vincristine Leurocristine; NSC-67574; 22-Oxovincaleukoblastine	Microtubule/Tubulin Antibiotic	Alkaloid Dimers Alkaloids Structural Classification Apocynaceae Catharanthus roseus (L.) G. Don Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Vincristine (Leurocristine) is a microtubule-destabilizing agent (MDA). Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine is used to research hematologic cancers, such as leukemia and lymphoma, and childhood sarcomas.

HY-108277

Ginsenoside F5	Apoptosis	Triterpenes Structural Classification Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Araliaceae Panax ginseng C. A. Meyer
Ginsenoside F5, from crude extracts of flower buds of Panax ginseng, remarkably inhibits the growth of HL-60 cells by the apoptosis pathway.

HY-111588

Xanthoangelol	Apoptosis Monoamine Oxidase Bacterial AMPK	Chalcones Phenols Polyphenols Structural Classification Flavonoids Umbelliferae Angelica keiskei Plants Source classification Inflammation/Immunology Infection Disease Research Fields Classification of Application Fields
Xanthoangelol, extracted from Angelica keiskei, suppresses obesity-induced inflammatory responses. Xanthoangelol possesses antibacterial activity. Xanthoangelol inhibits monoamine oxidases. Xanthoangelol induces apoptosis in neuroblastoma and leukemia cells.

HY-N8593

Undecane	TNF Receptor	Natural Products Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Undecane has anti-allergic and anti-inflammatory activities on sensitized rat basophilic leukemia (RBL-2H3) mast cells and HaCaT keratinocytes. In sensitized mast cells, Undecane inhibits degranulation and the secretion of histamine and TNF-α^[

HY-N0071

Crotonoside Isoguanosine	FLT3 HDAC	Alkaloids Other Alkaloids Structural Classification Croton tiglium Linn. Euphorbiaceae Plants Source classification Disease Research Fields Cancer Classification of Application Fields
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML.

HY-N3584

Paris saponin VII Chonglou Saponin VII	Akt p38 MAPK P-glycoprotein Bcl-2 Family Caspase PARP Autophagy Apoptosis	Steroids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Liliaceae Trillium tschonoskii Maxim.
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.

HY-N11370

Mesobuthus Eupeus Venom Lesser Asian scorpion Venom	Others	Scorpion Venoms Animals Animal Venoms
Mesobuthus Eupeus Venom (Lesser Asian scorpion Venom) is a scorpion venom that can be obtained from Lesser Asian scorpion. Mesobuthus Eupeus Venom induces selective toxicity in chronic lymphocytic leukemia B-lymphocytes through lysosomal/mitochondrial dysfunction and reactive oxygen species formation.

HY-125098

Illudin S	DNA Alkylator/Crosslinker Apoptosis	Terpenoids Sesquiterpenes Classification of Application Fields Disease Research Fields Infection Source classification Microorganisms
Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells.

HY-N8098

Pulchinenoside E2	Others	Terpenoids Triterpenes Classification of Application Fields Disease Research Fields Cancer Source classification Plants Ranunculaceae Pulsatilla chinensis (Bunge) Regel
Pulchinenoside E2 (Compound 8) is a triterpene saponin isolated from the roots of Pulsatilla chinensis. Pulchinenoside E2 shows cytotoxic to HL-60 cells with an IC₅₀ value of 2.6 µg/mL.

HY-112052

Aminomalonic acid	Endogenous Metabolite	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Source classification Endogenous metabolite
Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (K_i= 0.0023 M) and mouse pancreas (K_i= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis.

HY-N2492

(E)-Methyl 4-coumarate Methyl trans-p-coumarate	Bacterial Apoptosis	Other Phenylpropanoids Phenylpropanoids Monophenols Phenols Infection Disease Research Fields Classification of Application Fields Source classification Plants Rubiaceae Morinda citrifolia Linn.
(E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-N10777

1-Ketoaethiopinone	Others	Structural Classification Terpenoids Diterpenoids Myrsinaceae Plants Source classification Ardisia crenata Sims
1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma).

HY-N2435

[8]-Shogaol	COX Apoptosis	Monophenols Phenols Disease Research Fields Cancer Classification of Application Fields Source classification Plants Zingiberaceae Zingiber officinale
[8]-Shogaol, one of the pungent phenolic compounds in ginger, exhibits anti-platelet activity (IC₅₀=5 μM) and inhibits COX-2 (IC₅₀=17.5 μM). [8]-Shogaol induces apoptosis in human leukemia cells.

HY-N10350

2,3-Dihydro-3-methoxywithaferin A	Others	Steroids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Solanaceae Withania somnifera
2,3-Dihydro-3-methoxywithaferin A is an analogue of 2,3-dihydrowithaferin-A. 2,3-Dihydro-3-methoxywithaferin A inhibits proiiferation of P388 cells[1].

HY-N6736

K-252c	PKC Bacterial Apoptosis	Indole Alkaloids Alkaloids Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
K-252c, a staurosporine analog isolated from Nocardiopsis sp., is a cell-permeable PKC inhibitor, with an IC₅₀ of 2.45 µM. K-252c induces apoptosis in human chronic myelogenous leukemia cancer cells. K-252c also inhibits β-lactamase, chymotrypsin, and malate dehydrogenase.

HY-N2513

β-Boswellic acid	Lipoxygenase DNA/RNA Synthesis	Triterpenes Terpenoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants other families Burseraceae Boswellia serrata
β-Boswellic acid is isolated from the gum resin of Boswellia serrata. β-Boswellic acid is a nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells.

HY-N10189

Viridin	PI3K Endogenous Metabolite	Steroids Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
Viridin is a secondary metabolite and naturally occurring furanosteroid. Viridin is potent inhibitor of the lipid kinase PI3K.

HY-N4287

Nordalbergin	Others	Phenylpropanoids Coumarins Phenols Polyphenols Classification of Application Fields Disease Research Fields Cancer Source classification Plants Leguminosae Dalbergia sissoo
Nordalbergin, a coumarin isolated from the wood bark of Dalbergia sissoo. Nordalbergin shows strong activity in the induction of differentiation of HL-60.

HY-13653

(-)-Epigallocatechin Gallate EGCG; Epigallocatechol Gallate	Endogenous Metabolite Apoptosis	Phenols Polyphenols Flavonones Structural Classification Flavonoids other families Endogenous metabolite Plants Source classification Inflammation/Immunology Disease Research Fields Cancer Anti-aging Classification of Application Fields
(-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma.

HY-N10677

S-30-Hydroxygambogic acid	Others	Structural Classification Ketones, Aldehydes, Acids Source classification Plants Guttiferae Garcinia hanburyi
S-30-Hydroxygambogic acid is polyprenylated xanthone epimer that can be isolated from gamboges of Garcinia hanburyi. S-30-Hydroxygambogic acid shows cytotoxicities to Human Leukemia K562 cell lines of IC₅₀ values of 4.49 and 3.61 μM for K562/R and K562/S, respectively. S-30-Hydroxygambogic acid can be used for the research of cancer.

HY-13518

Piceatannol Astringenin; trans-Piceatannol	Syk Autophagy Apoptosis Endogenous Metabolite	Stilbenes Structural Classification Rheum palmatum L. Plants Source classification Polygonaceae Disease Research Fields Cancer Classification of Application Fields
Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI). Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties. Piceatannol induces apoptosis in DLBCL cell lines. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells.

HY-N10678

R-30-Hydroxygambogic acid	Others	Ketones, Aldehydes, Acids Structural Classification Guttiferae Garcinia hanburyi Plants Source classification
R-30-Hydroxygambogic acid is polyprenylated xanthone epimer that can be isolated from gamboges of Garcinia hanburyi. R-30-Hydroxygambogic acid shows cytotoxicities to Human Leukemia K562 cell lines of IC₅₀ values of 2.89 and 1.27 μM for K562/R and K562/S, respectively. R-30-Hydroxygambogic acid can be used for the research of cancer.

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	RANKL/RANK	Phenols Polyphenols Flavonones Structural Classification Flavonoids Sophora flavescens Leguminosae Plants Source classification Inflammation/Immunology Metabolic Disease Disease Research Fields Classification of Application Fields
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells.

HY-N8493

Mycalolide B	Others	Alkaloids Other Alkaloids Classification of Application Fields Disease Research Fields Other Diseases Source classification Animals
Mycalolide-B is a specific inhibitor of actomyosin ATPase isolated from marine sponge. Mycalolide-B inhibits ATP-induced contraction and Mg²⁺-ATPase activity in the absence of Ca²⁺.

HY-12372

Sanggenon G	IAP Caspase	Structural Classification Flavonones Flavonoids Morus alba L. Plants Source classification Moraceae
Sanggenon G is a cell-permeable and potent inhibitor of X-linked inhibitor of apoptosis protein (XIAP). Sanggenon G binds specifically to the BIR3 domain of XIAP with a binding affinity of 34.26 μM. Sanggenon G enhances caspase activation.

HY-N7175

5,8-Epidioxyergosta-6,9(11),22-trien-3-ol 9,11-Dehydroergosterol peroxide; 9(11)-DHEP	Apoptosis Endogenous Metabolite	Steroids Classification of Application Fields Disease Research Fields Cancer Source classification Plants Solanaceae Solanum lyratum Thunberg
5,8-Epidioxyergosta-6,9(11),22-trien-3-ol (9,11-Dehydroergosterol peroxide), an important steroid from medicinal mushroom, exerts antitumor activity in several tumor types. 5,8-Epidioxyergosta-6,9(11),22-trien-3-ol inhibits HT29 cell growth by inducing CDKN1A expression, thus causing cell cycle arrest and apoptosis.

HY-13629

Etoposide VP-16; VP-16-213	Topoisomerase Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Phenylpropanoids Monophenols Phenols Structural Classification Lignans Sinopodophyllum hexandrum (Royle) Ying Plants Berberidaceae Source classification Infection Disease Research Fields Classification of Application Fields
Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy.

HY-19825

Rebeccamycin	Topoisomerase ADC Cytotoxin Antibiotic	Antibiotics Structural Classification Other Antibiotics Microorganisms Source classification Disease Research Fields Cancer Classification of Application Fields
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Neurological Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-N10264

Avrainvillamide (+)-Avrainvillamide; CJ-17,665	Antibiotic	Pyrrole Alkaloids Indole Alkaloids Alkaloids Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Avrainvillamide ((+)-Avrainvillamide) is a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Avrainvillamide affects cell biology both by directly binding NPM1 and Crm1 as well as by inhibiting the association of these proteins with certain native cellular partners. Avrainvillamide, an antibiotic, inhibits growth of multi-agent resistant Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, with MICs of 12.5, 12.5 and 25 μg/ml, respectively.

HY-122919

Momordicoside L	Others	Triterpenes Structural Classification Terpenoids Source classification Plants Cucurbitaceae Momordica charantia Linn.
Momordicoside L is a Cucurbitane Triterpenoid, that can be isolated from the leaves of Momordica charantia. Momordicoside L shows anticancer activity.

HY-16050

Plitidepsin Aplidine; PM90001	DNA/RNA Synthesis SARS-CoV	Pyrrole Alkaloids Alkaloids Structural Classification Microorganisms Source classification Infection Disease Research Fields Classification of Application Fields
Plitidepsin (Aplidine) is a potent anti-cancer agent by targeting eEF1A2 ( K_D=80 nM). Plitidepsin possesses antiviral activity and is against SARS-CoV-2 with an IC₉₀ of 0.88 nM. Plitidepsin is usually used for multiple myeloma and advanced cancer research, and has the potential for COVID-19 research.

HY-N2306

Aclacinomycin A Aclarubicin	Topoisomerase DNA/RNA Synthesis Proteasome Antibiotic	Quinones Anthraquinones Microorganisms
Aclacinomycin A (Aclarubicin) is an orally active and potent anthracycline antitumor antibiotic. Aclacinomycin A is an inhibitor of topoisomerase I and II. Aclacinomycin A inhibits synthesis of nucleic acid, especially RNA. Aclacinomycin A might inhibit the 26S protease complex as well as the ubiquitin-ATP-dependent proteolysis.

HY-N3451

Isothymusin	Lipoxygenase	Flavonoids Flavones Source classification Plants
Isothymusin is a potent anti-oxidant agent. Isothymusin shows radical scavenging activities. Isothymusin shows anti-proliferative activities in cancer cell lines. Isothymusin inhibited the enzymes associated with the promotion stage of cancer, including cycloxygenase- 2 and lipoxygenase-5.

HY-N0171B

Beta-Sitosterol (purity>75%) β-Sitosterol (purity>75%); 22,23-Dihydrostigmasterol (purity>75%)	Apoptosis	Steroids Classification of Application Fields Disease Research Fields Cardiovascular Disease Inflammation/Immunology Source classification Plants other families
Beta-Sitosterol (purity>75%) includes 75% β-sitosterol and 10% campesterol. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>75%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171A

Beta-Sitosterol (purity>98%) β-Sitosterol (purity>98%); 22,23-Dihydrostigmasterol (purity>98%)	Apoptosis Endogenous Metabolite	Steroids Structural Classification Leguminosae Plants Source classification Glycine max (L.) merr Inflammation/Immunology Disease Research Fields Classification of Application Fields Cardiovascular Disease
Beta-Sitosterol (purity>98%) is a plant sterol. Beta-Sitosterol (purity>98%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

HY-N0171

Beta-Sitosterol (purity>80%) β-Sitosterol (purity>80%); 22,23-Dihydrostigmasterol (purity>80%)	Endogenous Metabolite Apoptosis	Steroids Classification of Application Fields Disease Research Fields Cardiovascular Disease Inflammation/Immunology Source classification Plants other families Endogenous metabolite
Beta-Sitosterol (purity>80%) includes β-sitosterol (≥80%), stigmasterol, campesterol and brassicasterol mainly. Beta-Sitosterol is a plant sterol. Beta-Sitosterol (purity>80%) interfere with multiple cell signaling pathways, including cell cycle, apoptosis, proliferation, survival, invasion, angiogenesis, metastasis and inflammation.

Species:	Human (22) Mouse (7) Rat (1) Cynomolgus (1)
Tag:	His (23) Tag Free (3) Avi (1) GST (2) Fc (3) Flag (1)
Source:	HEK293 (19) Sf9 insect cells (3) P. pastoris (1) E. coli (8)

Cat. No.	Product Name	Species	Source

HY-P73276

LIF Protein, Human (HEK293)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Human HEK293
HY-P73279

LIF Protein, Mouse (HEK293)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Mouse HEK293
HY-P700135AF

Animal-Free LIF Protein, Human (His)
leukemia inhibitory factor; HILDA; D factor; MLPLI
Human E. coli
HY-P700220AF

Animal-Free LIF Protein, Mouse (His)
leukemia inhibitory factor; HILDA; D factor; MLPLI
Mouse E. coli
HY-P73277

LIF Protein, Human (HEK293, Fc)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Human HEK293
HY-P73278

LIF Protein, Human (HEK293, His)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Human HEK293
HY-P73280

LIF Protein, Mouse (HEK293, His)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Mouse HEK293
HY-P75907

LIFR Protein, Rat (HEK293, His)
leukemia inhibitory factor receptor; LIF-R; CD118
Rat HEK293
HY-P77058

LIFR Protein, Human (HEK293, Fc)
leukemia inhibitory factor receptor; LIF-R; CD118
Human HEK293
HY-P77059

LIFR Protein, Human (HEK293, His)
leukemia inhibitory factor receptor; LIF-R; CD118
Human HEK293
HY-P77061

LIFR Protein, Mouse (HEK293, His)
leukemia inhibitory factor receptor; LIF-R; CD118
Mouse HEK293
HY-P73276A

LIF Protein, Human (HEK293, solution)
LIF; leukemia inhibitory factor; HILDA; D factor; MLPLI
Human HEK293

HY-P700418

LIFR Protein, Human (HEK293, hFc-Flag) LIFR; leukemia inhibitory factor receptor alpha; leukemia inhibitory factor receptor; CD118; LIF receptor; CD118 antigen; SWS; SJS2; STWS; LIF-R; FLJ98106; FLJ99923	Human	HEK293

HY-P77060

LIFR Protein, Human (Biotinylated, HEK293, His)
leukemia inhibitory factor receptor; LIF-R; CD118
Human HEK293
HY-P73275

Leukotriene A4 Hydrolase/LTA4H Protein, Human (sf9, His)
leukemia inhibitory factor; Leukotriene A-4 hydrolase; LTA-4 hydrolase; LTA4H
Human Sf9 insect cells
HY-P74776

Leukotriene A4 Hydrolase/LTA4H Protein, Mouse (sf9, His)
leukemia inhibitory factor; Leukotriene A-4 hydrolase; LTA-4 hydrolase; LTA4H
Mouse Sf9 insect cells

HY-P71121

Stathmin Protein, Human (C-His) Stathmin; leukemia-Associated Phosphoprotein p18; Metablastin; Oncoprotein 18; Op18; Phosphoprotein p19; pp19; Prosolin; Protein Pr22; pp17; STMN1; C1orf215; LAP18; OP18	Human	E. coli

HY-P71121A

Stathmin Protein, Human (His) "Stathmin; leukemia-Associated Phosphoprotein p18; Metablastin; Oncoprotein 18; Op18; Phosphoprotein p19; pp19; Prosolin; Protein Pr22; pp17; STMN1; C1orf215; LAP18; OP18 "	Human	E. coli

HY-P71757

MME Protein, Human (P.pastoris, His)
Atriopeptidase; CALLA; CD10; CD10 antigen; Common acute lymphocytic leukemia antigen
Human P. pastoris
HY-P74530

TCL1A Protein, Human (His)
T-cell leukemia/lymphoma protein 1A; Oncogene TCL-1; TCL1A; TCL1
Human E. coli

HY-P70637

TPO/Thrombopoietin Protein, Human (HEK293, His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

HY-P700155AF

Animal-Free TPO/Thrombopoietin Protein, Human (His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO	Human	E. coli

HY-P70637A

TPO/Thrombopoietin Protein, Human (HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO	Human	HEK293
TPO/Thrombopoietin Protein, Human (HEK 293, His) is a recombinant protein produced in HEK293 cells with a His tag. TPO is a growth factor for the megakaryocytic/platelet lineage.

HY-P70497

CD7 Protein, Human (HEK293, His)
T-Cell Antigen CD7; GP40; T-Cell leukemia Antigen; T-Cell Surface Antigen Leu-9; TP41; CD7
Human HEK293
HY-P72361

CD7 Protein, Human (Biotinylated, HEK293, His-Avi)
T-Cell Antigen CD7; GP40; T-Cell leukemia Antigen; T-Cell Surface Antigen Leu-9; TP41
Human HEK293

HY-P70686

TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293

HY-P70686A

TPO/Thrombopoietin Protein, Mouse (335a.a, HEK293, C-His) Thrombopoietin; C-mpl ligand; Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor; Myeloproliferative leukemia virus oncogene ligand; THPO	Mouse	HEK293

HY-P7808

CD7 Protein, Cynomolgus (HEK293, His) rCynIg-like domain-containing protein/CD7, His; T-Cell Antigen CD7; GP40; T-Cell leukemia Antigen; T-Cell Surface Antigen Leu-9; TP41; CD7	Cynomolgus	HEK293

HY-P71685

ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	E. coli
ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P77308

ABL1 Protein, Human (sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; ABL; JTK7; p150; Proto oncogene tyrosine protein kinase ABL1	Human	Sf9 insect cells

HY-P72119

CCND1 Protein, Human (His) AI327039; B cell leukemia 1; B-cell lymphoma 1 protein; BCL 1; BCL-1; BCL-1 oncogene; BCL1; BCL1 oncogene; ccnd1; CCND1/FSTL3 fusion gene; CCND1/FSTL3 fusion gene; included; CCND1/IGHG1 fusion gene; CCND1/IGLC1 fusion gene; CCND1_HUMAN; cD1; Cyl 1; D11S287E; G1/S specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31	Human	E. coli

Cat. No.	Product Name

HY-14519S

Methotrexate-d3

Methotrexate-d₃ (Amethopterin-d3) is the deuterium labeled Methotrexate. Methotrexate (Amethopterin), an antimetabolite and antifolate agent, inhibits the enzyme dihydrofolate reductase, thereby preventing the conversion of folic acid into tetrahydrofolate, and inhibiting DNA synthesis. Methotrexate, also an immunosuppressant and antineoplastic agent, is used for the research of rheumatoid arthritis and a number of different cancers (such as acute lymphoblastic leukemia)[1][2][3].

HY-13593S

Chlorambucil-d8
Chlorambucil-d₈ is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-13593S1

Chlorambucil-d8-1
Chlorambucil-d₈-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-N8593S

Undecane-d24
Undecane-d₂₄ is the deuterium labeled Undecane[1]. Undecane has anti-allergic and anti-inflammatory activities on sensitized rat basophilic leukemia (RBL-2H3) mast cells and HaCaT keratinocytes. In sensitized mast cells, Undecane inhibits degranulation and the secretion of histamine and TNF-α[2].

HY-17600S

Acalabrutinib-d4

Acalabrutinib-d₄ is a deuterium labeled Acalabrutinib. Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor[1].

leukemia

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products